

# Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS–STING and Toll-like receptors 3 and 4

Received: 21 October 2024

Accepted: 20 January 2026

Published online: 6 March 2026

 Check for updates

Alexis Betrancourt <sup>1,2,3,13</sup>, M. Talha Cinko <sup>1,2,13</sup>, Ana Beatriz Varanda<sup>1,2</sup>, Maykel Arias<sup>4,5,6</sup>, Iratxe Uranga-Murillo<sup>4,5,6</sup>, Natacha Peña<sup>4,5,6</sup>, Lucia-Maria Kaps <sup>1,2</sup>, Long Fung Chau<sup>7</sup>, Bianca Buratti <sup>1,2</sup>, Johannes Brägelmann <sup>8,9</sup>, Diego de Miguel <sup>1,2,3,5</sup>, Kerstin Becker<sup>10</sup>, Ramona Casper<sup>10</sup>, Rocio Martin<sup>11</sup>, Antonio Alcami <sup>11</sup>, Brian J. Ferguson <sup>7</sup>, Julian Pardo<sup>4,5,6</sup>, Eva Rieser <sup>1,2,3,12,14</sup>  & Henning Walczak <sup>1,2,3,14</sup> 

Pattern recognition receptor (PRR)-induced interferon (IFN) is critical for effective immunity. The PRRs Toll-like receptor (TLR) 3, TLR4 and cyclic GMP–AMP synthase (cGAS), together with the stimulator of IFN genes (STING), signal through TANK-binding kinase 1 (TBK1), which activates the type-I/III IFN-inducing transcription factor interferon-response factor 3 (IRF3). The mechanism by which these PRRs activate TBK1 remains unresolved. Here we show that lysine-11 (K11)-linked ubiquitination drives TBK1 activation by these PRRs. The E3 ligase ANKIB1 attaches K11-linked ubiquitin chains to components of the TLR3- and cGAS–STING-induced signalosomes. This facilitates Optineurin recruitment to these complexes, in turn enabling recruitment and activation of TBK1 and IRF3, defining an uncharacterized signalling axis. In mice, ANKIB1 deficiency dampens IFN induction via TLR3 and cGAS–STING, reducing interferonopathy and compromising protection against HSV-1, respectively. Together, our results demonstrate an unanticipated and critical role for ANKIB1-generated K11-linked ubiquitination in the immune response activated by cGAS–STING, TLR3 and TLR4.

Interferon (IFN) production is a key defence mechanism of innate immunity. Different pattern recognition receptors (PRRs) detect distinct pathogen- and damage-associated molecular patterns during infection and during tissue damage, rapidly mobilizing innate defences<sup>1–3</sup>. Toll-like receptors (TLRs) are archetypal and well-characterized PRRs<sup>4</sup>. The triggering of two of them, TLR3 and TLR4, results in the activation of TANK-binding kinase 1 (TBK1) in a biochemical context capable of directly activating IRF3, the transcription factor responsible for the induction of type-I and type-III IFNs<sup>5</sup>. This unique biochemical feature of the double-stranded (ds)RNA-sensing TLR3 and the lipopolysaccharide (LPS)-sensing TLR4 is shared with a small subset of other PRRs, most

notably the cytosolic DNA sensor cyclic GMP–AMP synthase (cGAS) and the two dsRNA-sensing RNA helicases retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA-5)<sup>6–9</sup>. However, despite its critical role in innate immunity, the biochemical mechanism by which activation of these PRRs confers this capacity on TBK1 remains unknown.

TBK1 is also involved in other cellular processes, including inhibition of tumour necrosis factor (TNF)-induced cell death via RIPK1 phosphorylation<sup>10</sup>. We previously showed that, by enabling the recruitment of various kinases, linear ubiquitin (linUb) chains generated by HOIP, a component of the linUb chain assembly complex (LUBAC),

A full list of affiliations appears at the end of the paper. ✉ e-mail: [erieser@uni-koeln.de](mailto:erieser@uni-koeln.de); [h.walczak@uni-koeln.de](mailto:h.walczak@uni-koeln.de)

are responsible for full gene activation and cell-death resistance in TNFR1 and TLR3 signalling<sup>11–13</sup>. While TBK1 is one such kinase in TNF signalling<sup>10</sup>, in TLR3 signalling LUBAC-generated linUb is dispensable for TBK1 activation<sup>13</sup>.

This unexpected observation, together with the fact that all proposed TBK1-recruiting adaptors in TLR3 signalling bind to polyubiquitin, including linUb<sup>10,14</sup>, led us to hypothesize that another, possibly linUb-generating and therefore probably HOIP-related E3 ligase may be required for TLR3-induced TBK1 activation. On the basis of this, we next screened the HOIP-comprising RING-between-RING (RBR)-domain-containing E3 subfamily for the elusive E3 ligase.

This resulted in the discovery of ANKIB1 as the E3 ligase responsible for TBK1 activation downstream of TLR3. Yet ANKIB1 does not generate linUb chains but instead attaches K11-linked ubiquitin (K11-Ub) chains to various components of the TLR3 signalosome, thereby enabling Optineurin (OPTN) recruitment and initiating an ANKIB1–K11-Ub–OPTN–TBK1–IRF3 signalling axis that bridges TLR3 stimulation to IRF3 activation and IFN induction. Remarkably, this signalling axis also drives activation of IRF3 following stimulation of TLR4 and cGAS, together with the stimulator of IFN genes (STING). In vivo, ANKIB1 deficiency limits TLR3-induced IFN induction and, consequently, reduces lethality in a TLR3-driven interferonopathy model, whereas it increases vulnerability of mice to herpes simplex virus-1 (HSV-1) infection, known to depend on cGAS–STING-mediated IFN induction for survival, providing compelling evidence that ANKIB1-mediated K11 ubiquitination is crucial for innate immune signalling in vivo.

## Results

### TLR3-mediated TBK1 and IRF3 activation requires ANKIB1, an unrecognized component of the TLR3-SC, to promote type-I and type-III IFN induction

After confirming that HOIP and its linUb-generating activity were dispensable for TBK1 activation downstream of TLR3, but not TNFR1 (Fig. 1a), we screened the RBR-E3 subfamily for the E3 ligase responsible for TLR3-induced TBK1 activation. Candidate RBR-E3s we could exclude a priori were HOIP, HOIL-1<sup>15</sup> and PARKIN because it is not expressed by HeLa cells<sup>16</sup>. Individual RNA-interference (RNAi)-mediated silencing of the remaining 11 RBR-E3 members revealed that only suppression of ANKIB1 substantially reduced TLR3-induced TBK1 activation, but not p65 phosphorylation (Extended Data Fig. 1a–c), implying a specific role for ANKIB1 in activation of TBK1 and not NF- $\kappa$ B.

To test whether ANKIB1 could indeed be the hitherto elusive E3 ligase required for TLR3-induced TBK1 activation, we next generated ANKIB1-knockout (KO) cell lines and analysed their response to TNF and polyinosinic:polycytidylic acid (poly(I:C)) stimulation in comparison to HOIP-KO and wild-type (WT) cells. This demonstrated that TLR3-induced TBK1 activation was virtually abolished in ANKIB1-KO cells, whereas TNF-induced TBK1 activation remained intact (Fig. 1b). Conversely, HOIP-KO impaired TNF- but not poly(I:C)-induced TBK1 activation (Fig. 1b). Extended kinetic analyses across different KO and WT cell lines confirmed that ANKIB1-KO did not merely delay but profoundly impaired TLR3- but not TNF-induced TBK1 phosphorylation (Extended Data Fig. 2a–c). Thus, TBK1 phosphorylation is enabled by two distinct RBR-E3 ligases in different signalling pathways; whereas HOIP facilitates TNF-induced TBK1 activation, ANKIB1 is required for TLR3-induced TBK1 phosphorylation.

Assessing the role of ANKIB1 in TLR3-mediated IRF3 activation and IFN induction<sup>17,18</sup> revealed that TLR3-induced IRF3 phosphorylation and the induction of both  $\beta$  (type-I) and  $\lambda$  (type-III) IFN gene expression almost completely depended on ANKIB1 (Fig. 1c–e). Stably re-expressing modified tandem affinity purification-tagged (moTAP)-ANKIB1 at near endogenous levels in ANKIB1-KO cells fully restored TLR3-induced TBK1 and IRF3 phosphorylation (Fig. 1f and Extended Data Fig. 2d) and type-I IFN production (Fig. 1g), underscoring the crucial role of ANKIB1 in this pathway. RNA-sequencing analysis

demonstrated that ANKIB1 is required for TLR3-mediated induction of type-I/III IFN genes and downstream IFN-stimulated genes. (Fig. 1h).

To epistatically place ANKIB1 in TLR3 signalling, we performed immunoprecipitation (IP) of moTAP-ANKIB1, which corroborated the TLR3-induced interaction of ANKIB1 with phosphorylated TBK1 (p-TBK1; Fig. 1i). To determine whether this interaction occurs at the TLR3 signalling complex (TLR3-SC) level, we generated TLR3-deficient HeLa cells expressing ectopic moTAP-TLR3. Apart from confirming recruitment of the known TLR3-SC components RIPK1 and HOIP<sup>13,19</sup>, immunoprecipitation of moTAP-TLR3 also revealed ANKIB1 as forming part of the TLR3-SC but not the TNFR1-SC (Fig. 1j and Extended Data Fig. 2e). Thus, ANKIB1 constitutes a previously unrecognized component of the TLR3-SC that interacts with TBK1 upon receptor activation and is required for TLR3-induced activation of TBK1 and IRF3 and induction of type-I/III IFNs.


### The RBR and UIM domains of ANKIB1 are crucial for TBK1 phosphorylation

Although ANKIB1 is a member of the RBR-E3 subfamily<sup>20</sup>, its catalytic activity had not previously been demonstrated. In an in vitro ubiquitination assay, full-length recombinant ANKIB1 was capable of generating ubiquitin chains in the presence of the E2s UBE2L3 and UBE2D3, with higher activity observed with UBE2D3 (Fig. 2a), yet not with UBE2L6 (Extended Data Fig. 3a). The multimeric proteins formed by ANKIB1/UBE2D3 were degraded by the general deubiquitinase (DUB) USP2, confirming they were composed of ubiquitin polymers (Extended Data Fig. 3b).

To assess whether the E3 ligase activity of ANKIB1 is required for TBK1 activation, we employed a similar approach to the previously studied RBR-E3 ligases, all known to exert their catalytic activity via their respective RING2<sup>21</sup>. We therefore next generated ANKIB1 with mutations in the conserved cysteine residues (C519S/C522S/C532S/C537S/C540S/C545S/C548S) of its RING2 (ANKIB1-RING2<sup>mut</sup>) (Extended Data Fig. 3c). Unexpectedly, ANKIB1-RING2<sup>mut</sup> expression in ANKIB1-deficient cells restored TLR3-induced TBK1 and IRF3 phosphorylation (Extended Data Fig. 3d). As we suspected that the point mutations we introduced in the RING2 of ANKIB1 might not have aborted its activity to the same extent as was seen in previous studies for other RBR-E3s<sup>22–24</sup>, we next expressed an ANKIB1 mutant lacking the entire RING2 domain (ANKIB1 $\Delta$ RING2) (Extended Data Fig. 3c), yet TBK1 and IRF3 activation were again restored to levels comparable to those observed in wt cells upon TLR3 stimulation (Extended Data Fig. 3e). To test whether ANKIB1 $\Delta$ RING2 bears residual catalytic activity, we performed in vitro ubiquitination assays. Despite lacking a RING2, this mutant RBR-E3 retained ubiquitin chain-forming activity with the more general E2 UBE2D3 but not with UBE2L3 (Extended Data Fig. 3f).

To fully abrogate any possible RBR-residing catalytic activity of ANKIB1, we next expressed mutant ANKIB1 lacking the entire RBR (ANKIB1 $\Delta$ RBR) in ANKIB1-KO cells (Extended Data Fig. 3c). This mutant failed to rescue TBK1 and IRF3 phosphorylation upon TLR3 activation, indicating that the catalytic activity of ANKIB1 indeed resides in its RBR and that the polyubiquitin chains it generates are essential for TBK1 activation (Fig. 2b). We next investigated whether the RBR domain is required for the recruitment of ANKIB1 to the TLR3-SC and/or its interaction with TBK1. Pull down (PD) revealed that the interaction of ANKIB1 with p-TBK1 was drastically reduced in absence of its RBR (Fig. 2c). By contrast, full-length ANKIB1 and ANKIB1 $\Delta$ RBR exhibited comparable interaction with TRAF3, a known component of the TLR3-SC<sup>25–27</sup>. Thus, the RBR of ANKIB1 is required for its TLR3-induced interaction with TBK1 and TBK1 activation but not for TLR3-SC recruitment.

Since the ANKIB1-RBR but not its RING2 was required, we next generated ANKIB1-deficient cells expressing a RING1-mutant ANKIB1 (ANKIB1-RING1<sup>mut</sup>) with mutations in several conserved residues (C333A/I335A/C336A/C351A/H353A) and, indeed, TLR3 stimulation failed to activate TBK1 in these cells (Fig. 2d). Hence, the RING1 of



**Fig. 1 | TLR3-mediated TBK1 and IRF3 activation requires ANKIB1, a member of the TLR3-SC, to promote type-I and type-III IFN induction. a, b,** HeLa WT, HOIP-deficient (HOIP<sup>-/-</sup>) and HOIP<sup>-/-</sup> cells reconstituted with enzymatically inactive HOIP<sup>C885S</sup> (**a**) or ANKIB1-deficient (ANK1<sup>-/-</sup>) (**b**) cells stimulated with either 10  $\mu\text{g ml}^{-1}$  poly(I:C) or 100 ng ml<sup>-1</sup> TNF for the indicated times and the lysates were analysed by western blotting. **c,** HT-29 ANK1<sup>-/-</sup> and WT cells were stimulated with 10  $\mu\text{g ml}^{-1}$  poly(I:C) for the indicated times and the lysates were analysed by immunoblotting. **d, e,** IFN $\beta$  (**d**) and IFN $\lambda$  (**e**) mRNAs levels were assessed by RT-qPCR 6 h after stimulation of HT-29 with 10  $\mu\text{g ml}^{-1}$  poly(I:C).  $P = 0.0199$  and  $P < 0.0001$ , respectively. **f,** HeLa ANK1<sup>-/-</sup> cells were reconstituted (rec.) with either moTAP-ANKIB1 WT (ANK WT) or empty vector (empty vec.) and treated with 10  $\mu\text{g ml}^{-1}$  poly(I:C) for the indicated times. Lysates were analysed by western blotting. **g,** Total RNA was isolated for IFN $\beta$  transcripts analysis by RT-qPCR

after the stimulation of cells from **f** for the respective time points.  $P = 0.4470$ ,  $P = 0.3506$ ,  $P < 0.0001$ ,  $P = 0.0018$  and  $P = 0.0099$ , respectively. **h,** RNA-seq analysis of HeLa cells reconstituted with either ANK WT or empty vector was performed after 10  $\mu\text{g ml}^{-1}$  poly(I:C) treatment for 2 h ( $n = 2$ ). **i,** HeLa cells stably expressing ANK WT were stimulated with 15  $\mu\text{g ml}^{-1}$  poly(I:C) and ANKIB1 was pulled down via its Flag-tag. **j,** HeLa TLR3<sup>-/-</sup> cells reconstituted with moTAP-TLR3 were treated with 15  $\mu\text{g ml}^{-1}$  poly(I:C) as indicated. moTAP-TLR3 was pulled down through its Flag-tag. FL, full length. All graphs represent mean  $\pm$  s.e.m. of three independent experiments.  $P$  values were calculated by two-way ANOVA with uncorrected Fisher's LSD multiple-comparisons tests with 95% confidence intervals. \* $P \leq 0.05$ , \*\* $P \leq 0.01$  and \*\*\* $P \leq 0.001$ . For western blots, one representative of at least three independent experiments is displayed. Non-specific bands are marked with an asterisk.



ANKIB1 is required and sufficient for its catalytic function and essential for promoting TBK1 activation.

Using mass spectrometry, we next determined the ubiquitin linkage type(s) ANKIB1 generates in the presence of UBE2D3 or UBE2L3. Surprisingly, K11-Ub was the most abundant linkage type formed by ANKIB1 in these *in vitro* assays with K63-Ub and K6-Ub linkages also detectable, albeit at substantially lower levels (Fig. 2e). No other linkage types, including linUb (M1-Ub) and K48-Ub, were detected. Performing a DUB assay using Cezanne (OTUD7B)<sup>28</sup>, a K11-Ub-specific DUB, resulted in the disappearance of the vast majority of ANKIB1-generated polyubiquitin chains (Fig. 2f). Thus, ANKIB1 preferentially generates K11-Ub chains and its catalytic activity facilitates TLR3-induced TBK1 activation, suggesting that ANKIB1-generated K11-Ub may be crucial for TBK1 recruitment and activation upon TLR3 stimulation.

Binding to ubiquitin or polyubiquitin chains is a well-established mechanism for recruiting proteins with the required specificity to signalling complexes<sup>29,30</sup>. As the ANKIB1-RBR was not required for TLR3-SC recruitment, we next examined the role of ANKIB1's ubiquitin-interacting motif (UIM), a domain type previously reported to mediate polyubiquitin-chain binding (Extended Data Fig. 3c)<sup>31</sup>. Following poly(I:C) treatment, while wt-ANKIB1 interacted with known TLR3-SC components, including TRAF3 and HOIP, UIM-deficient ANKIB1 (ANKIB1 $\Delta$ UIM) failed to associate with these components, implying this domain is essential for TLR3-SC recruitment of ANKIB1 (Fig. 2g).

As TBK1 is recruited to different immune receptor signalling complexes via distinct ubiquitin-binding adaptor proteins, we next sought to identify which ANKIB1-interacting protein(s) might function as TBK1 recruiter(s) in the TLR3 pathway. OPTN was previously reported as adaptor for TBK1 in TLR3 and TLR4, but not in TNFR1 signalling<sup>10,32</sup>, whereas NAP1 was previously proposed to serve as adaptor for TBK1 in TLR3 and TNFR1 signalling<sup>10,33</sup>. To determine possible adaptor interactions, we performed ANKIB1 PD upon TLR3 stimulation followed by western blotting for these the different possible adaptors. This identified a selective interaction between ANKIB1 and OPTN but not NAP1 (Fig. 2g,h). Hence, ANKIB1 is recruited to the TLR3-SC via its UIM domain and, once recruited, utilizes its RBR domain to mediate TBK1 activation, probably via OPTN as adaptor.

### Optineurin requires ANKIB1-generated K11-Ub for recruitment to the TLR3-SC and serves as essential adaptor for TBK1

Recruitment of OPTN, along with recruitment and activation of TBK1, correlates with the presence of ANKIB1 at the TLR3-SC (Fig. 2g,h). However, other proteins, including TANK, NAP1 and SINTBAD, have also been proposed as adaptors for TBK1 in TLR3 signalling<sup>34–36</sup>. To assess the contribution of these adaptors to TBK1 activation by TLR3, we next investigated poly(I:C)-induced TBK1 activation in triple knockout (TKO) cells lacking these three adaptors. Remarkably, TLR3-induced activation of TBK1 and IRF3 was unaffected in these cells whereas, consistent with our prior observations<sup>10</sup>, TNF-induced TBK1 activation was completely lost in the absence of these three proteins (Fig. 3a). Owing to the association between OPTN and ANKIB1 at the TLR3-SC and prior evidence implicating OPTN as TBK1 adaptor in TLR3 signalling<sup>32,37,38</sup>, we next generated quadruple knockout (QKO) cells lacking TANK, NAP1, SINTBAD and OPTN. In these QKO cells, TBK1 phosphorylation was completely abolished (Fig. 3b) upon poly(I:C) stimulation, indicating a critical role for OPTN as an adaptor in TBK1 recruitment. To test whether OPTN alone is sufficient and essential for TBK1 activation, we next generated OPTN single-KO cells. Strikingly, loss of OPTN alone recapitulated the phenotype of ANKIB1-deficient or QKO cells, with complete impairment of TBK1 and IRF3 activation in response to stimulation of TLR3 but not TNFR1 (Fig. 3c). Together, these results establish OPTN as the essential adaptor for TBK1 activation in TLR3 signalling.

Since the catalytic activity of ANKIB1 is required to promote TLR3-induced TBK1 activation (Fig. 2d) and because previous

studies have implicated the UBAN domain of OPTN in TBK1 recruitment during TLR3 signalling<sup>32,39</sup>, we next tested whether ANKIB1 and its K11-Ub-generating activity are necessary for OPTN and TBK1 recruitment. A comparison of TLR3-SC formation in WT versus ANKIB1-KO cells revealed markedly reduced recruitment of p-TBK1 and OPTN in ANKIB1 deficiency (Fig. 3d).

To investigate whether its K11-Ub-generating capacity is also required, we purified the TLR3-SC, treated it with the K11-specific DUB Cezanne and analysed the resulting supernatant for proteins released from the complex. Strikingly, Cezanne-mediated hydrolysis of K11-Ub chains caused specific release of OPTN, but not NEMO, from the TLR3-SC (Fig. 3e). Hence, ANKIB1 and its K11-Ub-generating activity are essential for the recruitment of OPTN, which is, in turn, required for TBK1 activation upon TLR3 stimulation.

In summary, we define a signalling axis in which ANKIB1 is recruited to the TLR3-SC, where it catalyses the formation of K11-linked polyubiquitin chains, facilitating the recruitment of OPTN which, in turn, mediates the recruitment and activation of TBK1. Importantly, this previously unrecognized ANKIB1–K11-Ub–OPTN–TBK1 signalling axis is essential for TLR3-induced IRF3 activation and IFN production.


### IFN induction by TLR4 and cGAS–STING is also driven by ANKIB1

We next investigated whether ANKIB1 plays a role in other PRRs known to induce type-I IFNs through TBK1 and IRF3. We first focused on the LPS-sensing TLR4, the only TLR capable of signalling through two pathways via distinct adaptors, a TRIF-dependent one that is similar to TLR3 signalling and an MyD88-dependent one. Importantly, only TRIF—but not MyD88—contains an IRF3-binding motif, which is essential for its recruitment, activation and subsequent induction of IFN genes<sup>9,25,40</sup>. In ANKIB1-KO cells, LPS-induced IRF3 phosphorylation and type-I/III IFN induction were substantially reduced in comparison with WT cells. TBK1 phosphorylation, however, was only partially decreased (Fig. 4a–c). Thus, similar to TLR3 signalling, the TRIF-dependent arm of TLR4 signalling requires ANKIB1 for effective TBK1 activation and downstream IRF3-dependent IFN induction. By contrast, MyD88-dependent signalling can also activate TBK1 but does not require ANKIB1<sup>40</sup>.

We next investigated the role of ANKIB1 in cGAS–STING signalling, which also relies on TBK1 and IRF3 for IFN induction. In ANKIB1-KO cells, stimulation with the STING activator 2'3' cyclic GMP–AMP (2'3'cGAMP) or the STING agonist ADU-S100 failed to induce robust phosphorylation of TBK1, IRF3 and STING (Fig. 4d and Extended Data Fig. 4a,b). Following STING activation, ANKIB1 PD revealed an interaction with activated STING, together with p-TBK1, suggesting that ANKIB1 is recruited to the STING-associated signalling complex (STING-SC) (Extended Data Fig. 4c). ANKIB1-deficient cells exhibited significantly reduced type-I/III IFN induction, not only following STING agonist treatment but also after infection with the cGAS-sensed poxvirus modified vaccinia virus Ankara (MVA) (Fig. 4e–g). Hence, ANKIB1 is also crucial for effective type-I/III IFN induction in TLR4 and cGAS–STING signalling.

Using cells expressing ANKIB1-RING1<sup>mut</sup> and ANKIB1 $\Delta$ UIM, we next tested the role of ANKIB1 catalytic activity and ubiquitin-binding capacity in cGAS–STING signalling. Both mutants failed to rescue TBK1 and IRF3 phosphorylation following STING stimulation, indicating that the E3 ligase activity and UIM of ANKIB1 are also essential for its function in cGAS–STING signalling (Fig. 4h and Extended Data Fig. 4d). Furthermore, ANKIB1 required its UIM for recruitment to the STING-SC, where it interacted with phosphorylated STING, TBK1 and OPTN (Fig. 4i).

By treating cells with the RIG-I ligand 3p-hpRNA, we next assessed whether the RIG-I helicase, which recognizes cytosolic dsRNA and activates IFN transcription through mitochondrial antiviral signalling protein (MAVS)-driven activation of TBK1 and IRF3<sup>41</sup>, may also require ANKIB1 for TBK1 activation. However, ANKIB1-KO cells exhibited TBK1 and IRF3 activation and type-I/III IFN induction similar to



**Fig. 3 | Optineurin is the crucial adaptor protein for TBK1 activation and requires K11-Ub generated by ANKIB1 for TLR3-SC recruitment.** **a**, HeLa WT cells and cells deficient for TANK/NAP1/SINTBAD (TKO) were stimulated with either  $100 \text{ ng ml}^{-1}$  TNF or  $10 \mu\text{g ml}^{-1}$  poly(I:C) for the indicated times and the lysates were subjected to western blot analysis. **b**, HeLa WT cells and cells deficient for TANK/NAP1/SINTBAD/OPTN (QKO) were stimulated with  $10 \mu\text{g ml}^{-1}$  poly(I:C) for the indicated times and the lysates were subjected to western blot analysis. **c**, HeLa WT, Optineurin-deficient (OPTN<sup>-/-</sup>) and ANK<sup>-/-</sup> cells were stimulated with either  $100 \text{ ng ml}^{-1}$  TNF or  $10 \mu\text{g ml}^{-1}$  poly(I:C) for the indicated times. The lysates were analysed by immunoblotting.

**d**, HeLa ANKIB1-proficient and deficient moTAP-TLR3 cells were stimulated with  $15 \mu\text{g ml}^{-1}$  poly(I:C). moTAP-TLR3 was pulled down via its Flag-tag and the analysis of co-immunoprecipitated proteins was determined by immunoblotting. FL, full length. **e**, HeLa moTAP-TLR3 cells were stimulated with  $15 \mu\text{g ml}^{-1}$  poly(I:C) for the indicated time points. moTAP-TLR3 was pulled down via its Flag-tag. After washing, the pulled-down samples were incubated with or without Cezanne (Cez) in DUB buffer for 1 h at  $30^\circ\text{C}$ . Co-immunoprecipitated proteins and the resultant supernatant were subjected to western blotting analysis. One representative of at least three independent experiments is displayed. Non-specific bands are marked with an asterisk.

WT controls (Fig. 4j–l), regardless of the 3p-hpRNA concentration used (Extended Data Fig. 4e,f). As further confirmation, we infected cells with Sendai virus (SeV) or influenza A virus (IAV), both of which are primarily sensed by RIG-I<sup>42</sup>. Upon infection, WT and ANKIB1-KO cells showed similar levels of TBK1 and IRF3 phosphorylation and MAVS protein levels remained unchanged (Extended Data Fig. 4g). Moreover, IFN $\beta$  induction was similar in WT and ANKIB1-KO cells (Fig. 4m). These findings suggest that ANKIB1 may not have a prominent role for RIG-I-mediated activation of TBK1 and IRF3 and subsequent IFN production.

To explain the divergence in ANKIB1 requirement across different PRRs, we hypothesized that distinct PRRs may engage different adaptor proteins for TBK1 recruitment and activation. Supporting this, we found that, as in TLR3 signalling, the absence of OPTN strongly impaired STING-induced activation of TBK1 and IRF3, whereas co-deletion of TANK, NAP1 and SINTBAD did not (Fig. 4n and Extended Data Fig. 4h). Conversely, TBK1 and IRF3 phosphorylation were strongly impaired in TANK/NAP1/SINTBAD TKO but remained unchanged in OPTN-KO cells upon RIG-I activation (Fig. 4o and Extended Data Fig. 4i). Thus, ANKIB1 promotes IFN production downstream of PRRs that depend on OPTN for TBK1 and IRF3 activation, namely TLR3, TRIF-mediated TLR4, and cGAS–STING. Instead, activation of TBK1, IRF3 and IFN production induced by stimulation of RIG-I is primarily mediated via TANK, NAP1 and/or SINTBAD.

#### ANKIB1 promotes ubiquitination of TRIF, STING, NEMO, OPTN and itself

Having established that the catalytic activity of ANKIB1 is essential for TBK1 activation downstream of TLR3 and cGAS–STING, we aimed to identify its potential substrates within the TLR3- and STING-SCs. To this end, we performed total ubiquitin PDs using tandem ubiquitin-binding entities (TUBE) following poly(I:C) or 2'3'cGAMP treatment. In WT cells, the adaptor proteins TRIF and STING were strongly ubiquitinated upon stimulation, whereas their ubiquitination was considerably reduced in ANKIB1-KO and ANKIB1-RING1<sup>mut</sup>-expressing cells (Fig. 5a,b). In addition, ubiquitination of NEMO and OPTN was also impaired in the absence of ANKIB1 or its catalytic activity (Fig. 5a,b), showing that the activity of ANKIB1 facilitates their ubiquitination. Intriguingly, ANKIB1 itself appeared to be constitutively ubiquitinated and underwent additional ubiquitination upon poly(I:C) or STING agonist treatment, while these ubiquitination events were absent in ANKIB1-RING1<sup>mut</sup>-expressing cells, (Fig. 5a,b), implying constitutive and PRR stimulation-dependent ANKIB1 auto-ubiquitination.

To identify the nature of the ubiquitin linkages involved, we performed TUBE PDs from poly(I:C)-treated cells followed by DUB assay using K63-specific AMSH, K11-specific Cezanne and non-linkage-specific USP2<sup>28,43,44</sup>. TRIF ubiquitination was sensitive to both AMSH and Cezanne, indicating the presence of both K63- and

K11-Ub-linked chains (Fig. 5c). OPTN ubiquitination was predominantly reduced by AMSH and USP2, with a modest Cezanne effect, suggesting predominant K63-Ub of OPTN yet also the presence of K11-Ub. For NEMO, only the high-molecular-weight ubiquitin chains were cleaved by either DUB (Fig. 5c), suggesting the presence of complex, probably K63–K11-branched or mixed-linkage ubiquitin chains that resist complete processing by individual DUBs. By performing K11-Ub-specific PDs following TLR3 activation, TRIF was found to be K11-ubiquitinated in WT but not in ANKIB1-KO cells, providing further proof of TRIF as substrate of ANKIB1 (Fig. 5d). Together, these results identify TRIF, STING, NEMO, OPTN and ANKIB1 itself as targets of the K11-Ub chain-generating activity of ANKIB1. K11-Ub, placed on components of the TLR3- and STING-SCs enables OPTN recruitment, thereby promoting activation of TBK1, IRF3 and subsequent IFN induction.

#### ANKIB1 is crucial for IRF3-activating, IFN-inducing TBK1 activation in primary murine immune cells upon activation of TLR3/4 and cGAS–STING, but not RIG-I

To understand the relevance of ANKIB1 in primary cells and in vivo, we generated *Ankibi1*<sup>-/-</sup> mice. ANKIB1 deficiency was not embryonically lethal and did not result in any overt phenotype (Extended Data Fig. 5a). However, ANKIB1 is differentially expressed across tissues and particularly enriched in the spleen, lungs and, to a lesser extent, the colon and Peyer's patches (Extended Data Fig. 5b). To assess whether ANKIB1 deletion altered basal immune homeostasis or inflammation, we evaluated spleen morphology and immune cell composition. Both spleen/body weight ratio and immune cell numbers were comparable between control and *Ankibi1*<sup>-/-</sup> mice (Extended Data Fig. 5c,d). Histological characterization of liver, spleen, lungs and intestine did not show any prominent alterations between *Ankibi1*<sup>-/-</sup> and control mice (Extended Data Fig. 5e).

We next assessed the role of ANKIB1 in innate immune signalling by examining primary murine immune cells ex vivo. Consistent with our findings in human cell lines, stimulation of TLR3 led to substantially decreased TBK1 phosphorylation in bone marrow-derived macrophages (BMDMs) from *Ankibi1*<sup>-/-</sup> compared with *Ankibi1*<sup>+/-</sup> controls (Extended Data Fig. 5f). In TLR4-stimulated splenocytes, TBK1 phosphorylation was preserved—probably via MyD88-dependent signalling—yet IRF3 phosphorylation was abolished and STAT1 phosphorylation, a downstream readout of type-I IFN signalling, was largely diminished in *Ankibi1*<sup>-/-</sup> cells (Extended Data Fig. 5g). Similarly, STING stimulation induced robust TBK1 activation and IFN production in *Ankibi1*<sup>+/-</sup> primary murine immune cells but was substantially attenuated in *Ankibi1*<sup>-/-</sup> cells (Extended Data Fig. 5h). By contrast, RIG-I signalling remained intact in *Ankibi1*<sup>-/-</sup> cells, with comparable phosphorylation of TBK1, IRF3 and STAT1 to controls (Extended Data Fig. 5i). These observations were further confirmed by cytokine quantification: control BMDMs secreted high levels of IFN $\beta$  upon TLR3, TLR4 or


**Fig. 4 | Type-I/III IFN induction by TLR4 and cGAS–STING, but not RIG-I, depends on ANKIB1.** **a**, HT-29 WT and ANK<sup>-/-</sup> cells were treated with 10  $\mu\text{g ml}^{-1}$  LPS as indicated and subjected to western blot analysis. **b,c**, IFN $\beta$  (**b**) and IFN $\lambda$  (**c**) mRNAs were measured by RT–qPCR 6 h after stimulation of HT-29 with 10  $\mu\text{g ml}^{-1}$  LPS.  $P = 0.0043$  and  $P = 0.0051$ , respectively. **d**, HeLa WT and ANK<sup>-/-</sup> cells were treated with 10  $\mu\text{g ml}^{-1}$  2'3'cGAMP as indicated and subjected to western blot analysis. **e,f**, IFN $\beta$  (**e**) and IFN $\lambda$  (**f**) mRNAs were respectively measured by RT–qPCR 6 h after stimulation of HT-29 with 10  $\mu\text{g ml}^{-1}$  ADU-S100.  $P < 0.0001$  and  $P = 0.0108$ , respectively. **g**, HeLa WT and ANK<sup>-/-</sup> cells were infected with attenuated MVA virus for the indicated time points before IFN $\beta$  transcripts were measured by RT–qPCR.  $P = 0.0004$  and  $P < 0.0001$ , respectively. hpi, hours post infection. **h**, HeLa cells stably expressing ANK WT or ANK RING1<sup>mut</sup> were stimulated with 10  $\mu\text{g ml}^{-1}$  ADU-S100 and the lysates were analysed by immunoblotting. **i**, HeLa cells stably expressing either ANK WT or ANK  $\Delta$ UIM treated with 10  $\mu\text{g ml}^{-1}$  2'3'cGAMP. moTAP-ANKIB1 was pulled down via its Flag-tag. Immunoprecipitated proteins were analysed by immunoblotting. **j**, A549


WT and ANK<sup>-/-</sup> cells were treated with 500  $\text{ng ml}^{-1}$  3p-hpRNA for the indicated times and subjected to western blot analysis. **k,l**, IFN $\beta$  (**k**) and IFN $\lambda$  (**l**) mRNAs were measured by RT–qPCR 6 h after stimulation of HeLa WT and ANK<sup>-/-</sup> cells with 500  $\text{ng ml}^{-1}$  3p-hpRNA.  $P = 0.8597$  and  $P = 0.9458$ , respectively. **m**, A549 WT and ANK<sup>-/-</sup> cells were infected with SeV for the indicated times before IFN $\beta$  transcripts were measured by RT–qPCR.  $P = 0.4326$  and  $P = 0.7257$ , respectively. **n**, HeLa WT, OPTN<sup>-/-</sup> and ANK<sup>-/-</sup> cells were stimulated with 10  $\mu\text{g ml}^{-1}$  ADU-S100. The lysates were subjected to immunoblotting. **o**, HeLa WT and TKO cells were treated with 500  $\text{ng ml}^{-1}$  3p-hpRNA for the indicated times and the lysates were subjected to western blot analysis. All graphs represent mean  $\pm$  s.e.m. of three independent experiments.  $P$  values were determined by two-way ANOVA with uncorrected Fisher's LSD multiple-comparisons tests with 95% confidence interval. \* $P \leq 0.05$ , \*\* $P \leq 0.01$  and \*\*\* $P \leq 0.001$ . For western blots, one representative of three independent experiments is shown. Non-specific bands are marked with an asterisk.

STING stimulation, whereas *Ankib1*<sup>-/-</sup> BMDMs showed blunted IFN $\beta$  production upon TLR3 and TLR4 stimulation and a substantial decrease therein upon STING activation (Fig. 6a–c). By contrast, IFN $\beta$  production in response to RIG-I stimulation was unaffected by ANKIB1 deficiency (Fig. 6d). These results demonstrate that ANKIB1 is a crucial driver of IRF3 activation and consequent IFN induction downstream of TLR3, TLR4 and cGAS–STING.

**ANKIB1 is crucial for TLR3- and cGAS–STING-mediated IFN induction in vivo**

During infection, type-I IFNs are critical for orchestrating an effective immune response<sup>45,46</sup>. However, excessive or uncontrolled type-I IFN production can be detrimental, as seen in various so-called interferonopathies<sup>47</sup>, such as Aicardi–Goutières syndrome and STING-associated vasculopathy with onset in infancy, as well as





**Fig. 5 | ANKIB1 promotes ubiquitination of TRIF, STING, NEMO, OPTN and itself.** **a**, HeLa WT, ANK<sup>-/-</sup> and ANK RING1<sup>mut</sup> cells were stimulated with 15 μg ml<sup>-1</sup> poly(I:C) for the indicated times. The ubiquitinated proteins were pulled down using GST-TUBE pre-coupled with glutathione beads. Co-precipitated proteins were analysed by western blot. **b**, HeLa WT, ANK<sup>-/-</sup> and ANK RING1<sup>mut</sup> cells were stimulated with 10 μg ml<sup>-1</sup> 2'3'cGAMP for the indicated times. The ubiquitinated proteins were pulled down using GST-TUBE pre-coupled with glutathione beads. Co-precipitated proteins were analysed by western blot. **c**, HeLa WT cells were stimulated with 15 μg ml<sup>-1</sup> poly(I:C) for 60 min. The ubiquitinated proteins were

pulled down using GST-TUBE pre-coupled with glutathione beads and the beads were incubated with K48 tetra-Ub chains before performing a deubiquitination assay using either 125 nM AMSH, Cezanne (Cez.) or 250 nM USP2. The samples were analysed by western blot. **d**, HeLa WT, and ANK<sup>-/-</sup> cells were stimulated with 15 μg ml<sup>-1</sup> poly(I:C) for the indicated times. K11-linked polyubiquitinated targets were co-precipitated using a K11 2A3/2E6 antibody pre-coupled with protein G. Co-immunoprecipitated proteins were analysed by western blotting. IP, immunoprecipitated. For western blots, one representative of three independent experiments is displayed. Non-specific bands are marked with an asterisk.

secondary haemophagocytic lymphohistiocytosis (sHLH)<sup>47–52</sup>. The latter is characterized by excessive macrophage activation, leading to hyperinflammation and multi-organ failure<sup>53</sup>. As no natural pathogen is known to elicit IFN exclusively through TLR3, we employed an *in vivo* model of sHLH (Fig. 6e) in which TLR3-driven type-I IFN converts an otherwise sublethal TLR4 stimulation (Extended Data Fig. 6a) into a lethal challenge<sup>47</sup>. Strikingly, ANKIB1 deficiency significantly protected from TLR3-driven sHLH, as 78% of *Ankib1*<sup>-/-</sup> mice survived whereas all control mice succumbed to the challenge (Fig. 6f). RNA-sequencing of spleens collected after poly(I:C) treatment revealed that, while poly(I:C) induced robust type-I/III IFN expression in control mice, this response was largely absent in *Ankib1*<sup>-/-</sup> mice (Fig. 6g). Importantly, while NF- $\kappa$ B target genes such as IL-6 and IL-1 $\beta$  were equally induced in both genotypes, IFN-stimulated genes were selectively upregulated in controls. Gene set enrichment analysis further showed a marked suppression of IFN $\alpha$  and IFN $\gamma$  response signatures in *Ankib1*<sup>-/-</sup> mice, whereas TNF, IL-6 and MAPK signalling pathways were not strongly affected (Fig. 6h and Extended Data Fig. 6b–e). Together, these results establish ANKIB1 as a key driver of TLR3-induced type-I/III IFN production and responses *in vivo*, and identify it as a critical mediator of TLR3-induced lethality in interferonopathy.

Given the established role of ANKIB1 in TRIF- but not MyD88-dependent TLR4 signalling, we next determined whether ANKIB1 deficiency influences TLR4-driven, MyD88-dependent pathology *in vivo*. To accomplish this, we employed an *E. coli*-induced sepsis model in which the lethality is driven by MyD88-dependent TLR4 signalling<sup>54</sup>. Notably, ANKIB1-deficient and control mice exhibited comparable susceptibility to *E. coli*-induced lethality (Fig. 6i), indicating selective requirement for ANKIB1 in TRIF-dependent, but not MyD88-dependent, TLR4 signalling *in vivo*.

We next assessed the role of ANKIB1 in the context of viral infection. First, we used IAV as an RNA virus model, in which viral RNA is known to be primarily sensed by RIG-I, leading to a potent IFN response essential for host survival<sup>45,55,56</sup>. In this model, weight loss and recovery were indistinguishable between control and *Ankib1*<sup>-/-</sup> mice (Fig. 6j), providing *in vivo* confirmation that ANKIB1 is not essential for RIG-I signalling.

Finally, we intranasally infected mice with HSV-1SC16, a DNA virus primarily sensed by the cGAS–STING pathway whose induction of IFN is indispensable for survival in this model<sup>57–59</sup>. As expected, 75% of control mice survived infection (Fig. 6k). Remarkably, *Ankib1*<sup>-/-</sup> mice exhibited severe susceptibility, with only 20% of the mice surviving the challenge (Fig. 6k), implicating ANKIB1 as a key regulator of antiviral defence against HSV-1. Interestingly, the susceptibility of *Ankib1*<sup>-/-</sup> mice to HSV-1 infection is similar to that previously reported for *Optn*<sup>-/-</sup> mice in the

same model<sup>60</sup>, which, in both cases, is lower than expected for complete loss of cGAS–STING signalling<sup>59</sup>. This result is probably reflective of a substantial, yet incomplete dependence of cGAS–STING-induced IFN induction on ANKIB1–OPTN signalling also *in vivo*, in line with our observations in human cell lines (Fig. 4n) and primary murine immune cells *ex vivo* (Fig. 6c and Extended Data Fig. 5h).

To determine the mechanism underlying this increased lethality, we collected brainstems—the primary site of HSV-1 replication in this model<sup>59</sup> at day 3 post infection and analysed cytokine expression. Notably, IFN $\beta$  response signalling was significantly downregulated in HSV-1-infected *Ankib1*<sup>-/-</sup> compared with control mice (Fig. 6l). However, NF- $\kappa$ B target genes showed heterogeneous expression, indicating that ANKIB1 primarily affected IFN signalling. We also observed a 50% reduction in IFN $\beta$  levels in pulmonary tissues from infected mice, while NF- $\kappa$ B-driven cytokines such as IL-6 remained largely unchanged (Fig. 6m and Extended Data Fig. 6f). Consequently, immune activation and cytotoxic effector responses were also impaired, as evidenced by reduced granzyme B expression in the lungs and the analysis of the downregulated genes in the brainstems of *Ankib1*<sup>-/-</sup> mice (Fig. 6n,o). Thus, ANKIB1 is an important driver of cGAS–STING-dependent IFN induction and antiviral immunity against HSV-1 infection *in vivo*.

In summary, the results demonstrate that ANKIB1 is crucial for IFN-dependent biological effects triggered by TLR3 and cGAS–STING *in vivo*, whereas this is not the case for RIG-I and the MyD88-dependent arm of TLR4.

## Discussion

We here describe ANKIB1 and the product of this catalytic activity, K11-Ub, as previously unknown crucial drivers of TBK1 and IRF3 activation and type-I/III IFN induction downstream of TLR3, TLR4 and cGAS–STING. This is achieved via a hitherto unknown signalling axis comprised of ANKIB1–K11-Ub–OPTN–TBK1, which acts as a molecular bridge linking activation of TLR3, TLR4, and cGAS–STING to TBK1 activation, thereby enabling IRF3 activation and IFN induction. We provide evidence for the physiological relevance of ANKIB1 as the apical component of a previously unrecognized signalling axis in *in vivo* disease models of TLR3-dependent interferonopathy and cGAS–STING-mediated, IFN induction-dependent antiviral immunity.


Mechanistically, ANKIB1 is recruited to the TLR3-SC via its UIM domain, where it K11-ubiquitinates TRIF, NEMO, OPTN and itself. K11-Ub was previously shown to regulate cell cycle progression by enabling proteasomal degradation<sup>61</sup>, with more recent studies suggesting that, rather than acting alone, K11-Ub triggers proteasomal degradation in

**Fig. 6 | ANKIB1 is crucial for TLR3- and cGAS–STING-mediated IFN induction *in vivo*.** **a–d**, Control (ctrl) and *Ankib1*<sup>-/-</sup> BMDMs were stimulated with 5  $\mu$ g ml<sup>-1</sup> poly(I:C) for 24 h (**a**), 200 ng ml<sup>-1</sup> LPS for 4 h (**b**), 5  $\mu$ g ml<sup>-1</sup> ADU-S100 for 6 h (**c**) or 200 ng ml<sup>-1</sup> 3p-hpRNA for 6 h (**d**) and the supernatants were collected to determine IFN $\beta$  concentration by ELISA. The graphs represent mean  $\pm$  s.e.m. of three or four independent biological replicates. *P* values were determined by two-way ANOVA with uncorrected Fisher's LSD multiple-comparisons tests with 95% confidence intervals. *P* < 0.0001, *P* < 0.0001, *P* < 0.0001 and *P* = 0.6573, respectively. **e**, A workflow of the sHLH model. **f**, Poly(I:C) (10 mg kg<sup>-1</sup>) was injected intraperitoneally to 8–12-week-old WT littermate control and *Ankib1*<sup>-/-</sup> mice, followed 24 h later by intraperitoneal administration of 5 mg kg<sup>-1</sup> LPS. The survival rates of the mice were monitored for 5 days and a log-rank Mantel–Cox test was used to determine the statistical significance. *P* = 0.0018. **g**, Spleens of 9–10-week-old WT littermate control and *Ankib1*<sup>-/-</sup> mice were collected for RNA extraction after 10 mg kg<sup>-1</sup> intraperitoneal poly(I:C) injection for 3 and 6 h. The RNA-sequencing analysis is represented as a heat map, using two independent biological replicates per group for each genotype. **h**, IFN $\alpha$  response gene set enrichment analysis was performed using spleen samples for both the 3-h and the 6-h time points. Statistical significance of the data was determined using the Kolmogorov–Smirnov test. **i**, WT littermate control and *Ankib1*<sup>-/-</sup> mice were challenged with 2  $\times$  10<sup>8</sup> colony-forming units

*Escherichia coli*-induced sepsis. The survival rates of the mice were monitored for 5 days and a log-rank Mantel–Cox test was used to determine the statistical significance. *P* = 0.9001. **j**, Eight to ten-week-old WT littermate control and *Ankib1*<sup>-/-</sup> mice were challenged with 1  $\times$  10<sup>6</sup> p.f.u. IAV. The weight loss of the mice was monitored for 15 days. Data show the mean  $\pm$  s.d. of independent biological replicates. *P* values were determined by two-way ANOVA. *P* = 0.2721. **k**, Twelve to sixteen-week-old male *Ankib1*<sup>-/-</sup> (*n* = 5) and WT littermate control mice (*n* = 8) were challenged with 1  $\times$  10<sup>6</sup> PFU HSV-1SC16. The survival rates of the mice were monitored for 14 days and a log-rank Mantel–Cox test was used to determine the statistical significance. *P* = 0.0395. **l**, GO analysis was performed using RNA samples from the brainstem of WT littermate control and *Ankib1*<sup>-/-</sup> mice at 3 days post infection (dpi) with HSV-1. **m, n**, The respective cytokines in lung homogenates of 12-week-old WT littermate control (*n* = 4) and *Ankib1*<sup>-/-</sup> (*n* = 5) mice were measured at day 5 post infection with HSV-1SC16 by multiplex ELISA. *P* = 0.007 and *P* = 0.0209, respectively. ELISA graphs represent mean  $\pm$  s.d. of independent biological replicates. *P* values were determined by an unpaired two-tailed Student's *t*-test. \**P*  $\leq$  0.05, \*\**P*  $\leq$  0.01, \*\*\**P*  $\leq$  0.001 and \*\*\*\**P*  $\leq$  0.0001. **o**, GO analysis was performed using RNA samples from brainstems of WT littermate control and *Ankib1*<sup>-/-</sup> mice at 5 dpi with HSV-1. Panel **e** created with BioRender.com.

concert with other chain types, including K48-Ub or K63-Ub<sup>62</sup> with non-degradative signalling roles<sup>63</sup>. We show that ANKIB1-generated K11-Ub is essential for the recruitment of OPTN to the TLR3-SC, which in turn serves as critical adaptor for TBK1 recruitment and activation, driving IRF3 phosphorylation and IFN production. Interestingly, Dynek et al. reported that K11-Ub confers a scaffold property to RIPK1 in TNFR1 signalling and that NEMO, which contains a UBAN domain similar to that of OPTN, is able to bind to such K11-Ub<sup>64</sup>.

We also identified a role for ANKIB1 in TRIF-dependent TLR4 signalling. TLR4 signals via both MyD88 and TRIF<sup>65,66</sup>, with TRIF containing the IRF3-binding motif for IFN production<sup>9,40</sup>. While TANK mediates TBK1 and IKKε activation in MyD88 signalling<sup>34</sup>, it is dispensable for TBK1 and IRF3 activation downstream of TRIF. Our findings align with prior studies showing that OPTN—but not TANK—is essential for IFN production in TRIF-dependent TLR4 signalling<sup>32,37</sup>. On the basis of our findings, we propose that the ANKIB1–K11-Ub–OPTN–TBK1 signalling



axis we identified as responsible for IFN induction downstream of TRIF in TLR3 signalling operates likewise in TLR4 signalling.

Finally, we demonstrated a key role for ANKIB1 in cGAS–STING signalling. Prior studies reported a direct TBK1–STING interaction via a C-terminal TBK1-binding motif<sup>67,67</sup>, whereas others highlighted a requirement for ubiquitination<sup>68–70</sup>. Our results reconcile these models by showing that the ANKIB1–OPTN dependence of cGAS–STING-induced TBK1 activation and IFN induction is substantial yet incomplete. It is possible that ANKIB1–OPTN-independent, cGAS–STING-induced TBK1 activation is due to direct binding of TBK1 to STING, as previously shown<sup>7,67</sup>; it remains to be shown, however, whether this is truly the case.

Consistent with previous work that OPTN deficiency impairs STING-induced IFN induction, thereby increasing susceptibility to HSV-1 infection<sup>60,71</sup>, we show that OPTN is required for effective TBK1 activation downstream of STING. We identify STING, NEMO, OPTN and ANKIB1 itself as substrates of ANKIB1 and show, by using ANKIB1-RING1<sup>mut</sup> cells, that the catalytic activity of ANKIB1 enables OPTN and TBK1 recruitment, contributing substantially to IRF3 activation and type-I and type-III IFN production. By contrast, ANKIB1 and OPTN are dispensable for robust RIG-I–MAVS signalling, whereas TANK, NAPI and/or SINTBAD are required for it, as previously reported<sup>36</sup>.

Interestingly, the biochemical mechanism of the catalytic activity of ANKIB1 is distinct from that of other RBR-E3s such as PARKIN or HOIP<sup>72,73</sup> as it depends on the RBR-RING1 rather than the RBR-RING2. The identification of this currently unique mechanism for ANKIB1 among the RBR-E3s proposes the existence of two distinct types of RBR-E3s, one relying on RING2 and the other one on RING1. Structural studies will be required to determine how ANKIB1 accomplishes this.

We identify ANKIB1 as crucial driver of activation of TBK1, IRF3 and type-I/III IFN induction in signalling triggered by TLR3, TRIF-dependent TLR4 and cGAS–STING, but not RIG-I. Contrasting with the latter, it was recently reported that ANKIB1 would interfere with RIG-I-induced IFN induction, that is, exert the opposite function to the one we identified for ANKIB1 in TLR3, TLR4 and cGAS–STING but not RIG-I–MAVS signalling, by mediating the proteasomal degradation of MAVS through K48-linked ubiquitination<sup>74</sup>. However, we neither observed such interference with RIG-I-induced IFN induction in ANKIB1-proficient cells nor did we detect proteasomal degradation of MAVS upon treatment of such cells with the RIG-I ligand 3p-hpRNA or by infection with the RIG-I-stimulating viruses IAV and SeV. We attribute this differential requirement to distinct biochemical mechanisms of TBK1 activation downstream of various PRRs. Whereas cGAS–STING and TRIF-dependent TLR3 and TLR4 signalling rely on OPTN-mediated TBK1 phosphorylation, which requires recruitment via ANKIB1-generated K11-linked ubiquitin chains, TBK1 activation downstream of RIG-I–MAVS primarily depends on the adaptor proteins TANK, NAPI and SINTBAD, whose recruitment, as we show, is ANKIB1-independent.

In summary, we here identify a previously unrecognized ANKIB1–K11-Ub–OPTN–TBK1 signalling axis as the crucial driver of IRF3-mediated IFN induction downstream of TLR3, TLR4 and cGAS–STING (Extended Data Fig. 5j). Notably, ANKIB1 deletion confers significant protection in an otherwise lethal TLR3-dependent interferonopathy mouse model. Future strategies aimed at inhibiting the catalytic function of ANKIB1 or degrading it altogether may open additional avenues for treating IFN-driven pathologies.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41556-026-01886-z>.

## References

- Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. *Science* **264**, 1918–1921 (1994).
- Haller, O., Arnheiter, H., Gresser, I. & Lindenmann, J. Virus-specific interferon action. Protection of newborn Mx carriers against lethal infection with influenza virus. *J. Exp. Med.* **154**, 199–203 (1981).
- Durbin, J. E. et al. Type I IFN modulates innate and specific antiviral immunity. *J. Immunol.* **164**, 4220–4228 (2000).
- Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat. Immunol.* **11**, 373–384 (2010).
- Perry, A. K., Chow, E. K., Goodnough, J. B., Yeh, W. C. & Cheng, G. Differential requirement for TANK-binding kinase-1 in type I interferon responses to Toll-like receptor activation and viral infection. *J. Exp. Med.* **199**, 1651–1658 (2004).
- Tenoever, B. R. et al. Multiple functions of the IKK-related kinase IKKε in interferon-mediated antiviral immunity. *Science* **315**, 1274–1278 (2007).
- Yum, S., Li, M., Fang, Y. & Chen, Z. J. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. *Proc. Natl Acad. Sci. USA* **118**, e2100225118 (2021).
- Tanaka, Y. & Chen, Z. J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. *Sci. Signal.* **5**, ra20 (2012).
- Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. *Science* **347**, aaa2630 (2015).
- Lafont, E. et al. TBK1 and IKKε prevent TNF-induced cell death by RIPK1 phosphorylation. *Nat. Cell Biol.* **20**, 1389–1399 (2018).
- Gerlach, B. et al. Linear ubiquitination prevents inflammation and regulates immune signalling. *Nature* **471**, 591–596 (2011).
- Haas, T. L. et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. *Mol. Cell* **36**, 831–844 (2009).
- Zinngrebe, J. et al. LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. *J. Exp. Med.* **213**, 2671–2689 (2016).
- Li, F. et al. Structural insights into the ubiquitin recognition by OPTN (optineurin) and its regulation by TBK1-mediated phosphorylation. *Autophagy* **14**, 66–79 (2018).
- Peltzer, N. et al. LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis. *Nature* **557**, 112–117 (2018).
- Pawlyk, A. C. et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. *J. Biol. Chem.* **278**, 48120–48128 (2003).
- Hemmi, H. et al. The roles of two IκB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. *J. Exp. Med.* **199**, 1641–1650 (2004).
- McWhirter, S. M. et al. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. *Proc. Natl Acad. Sci. USA* **101**, 233–238 (2004).
- Cusson-Hermance, N., Khurana, S., Lee, T. H., Fitzgerald, K. A. & Kelliher, M. A. Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-κB activation but does not contribute to interferon regulatory factor 3 activation. *J. Biol. Chem.* **280**, 36560–36566 (2005).
- Spratt, D. onaldE., Walden, H. & Shaw, G. aryS. RBR E3 ubiquitin ligases: new structures, new insights, new questions. *Biochem. J.* **458**, 421–437 (2014).
- Walden, H. & Rittinger, K. RBR ligase-mediated ubiquitin transfer: a tale with many twists and turns. *Nat. Struct. Mol. Biol.* **25**, 440–445 (2018).

22. Kamadurai, H. B. et al. Insights into ubiquitin transfer cascades from a structure of a UbcH5B approximately ubiquitin–HECT(NEDD4L) complex. *Mol. Cell* **36**, 1095–1102 (2009).
23. Eddins, M. J., Carlile, C. M., Gomez, K. M., Pickart, C. M. & Wolberger, C. Mms2–Ubc13 covalently bound to ubiquitin reveals the structural basis of linkage-specific polyubiquitin chain formation. *Nat. Struct. Mol. Biol.* **13**, 915–920 (2006).
24. Fallon, L. et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K–Akt signalling. *Nat. Cell Biol.* **8**, 834–842 (2006).
25. Tseng, P.-H. et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. *Nat. Immunol.* **11**, 70–75 (2009).
26. Häcker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. *Nature* **439**, 204–207 (2005).
27. Oganessian, G. et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. *Nature* **439**, 208–211 (2005).
28. Mevissen, T. E. T. et al. Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne. *Nature* **538**, 402–405 (2016).
29. Rahighi, S. et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF- $\kappa$ B activation. *Cell* **136**, 1098–1109 (2009).
30. Dikic, I., Wakatsuki, S. & Walters, K. J. Ubiquitin-binding domains—from structures to functions. *Nat. Rev. Mol. Cell Biol.* **10**, 659–671 (2009).
31. Miller, S. L., Malotky, E. & O’Byrne, J. P. Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation. *J. Biol. Chem.* **279**, 33528–33537 (2004).
32. Gleason, C. E., Ordureau, A., Gourlay, R., Arthur, J. S. C. & Cohen, P. Polyubiquitin binding to optineurin is required for optimal activation of tank-binding kinase 1 and production of interferon  $\beta$ . *J. Biol. Chem.* **286**, 35663–35674 (2011).
33. Sasai, M. et al. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction. *J. Immunol.* **177**, 8676–8683 (2006).
34. Clark, K., Takeuchi, O., Akira, S. & Cohen, P. The TRAF-associated protein TANK facilitates cross-talk within the I $\kappa$ B kinase family during Toll-like receptor signaling. *Proc. Natl Acad. Sci. USA* **108**, 17093–17098 (2011).
35. Goncalves, A. et al. Functional dissection of the TBK1 molecular network. *PLoS ONE* **6**, e23971 (2011).
36. Ryzhakov, G. & Randow, F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. *EMBO J.* **26**, 3180–3190 (2007).
37. Slowicka, K. et al. Optineurin deficiency in mice is associated with increased sensitivity to Salmonella but does not affect proinflammatory NF- $\kappa$ B signaling. *Eur. J. Immunol.* **46**, 971–980 (2016).
38. Meena, N. P. et al. The TBK1-binding domain of optineurin promotes type I interferon responses. *FEBS Lett.* **590**, 1498–1508 (2016).
39. Munitic, I. et al. Optineurin insufficiency impairs IRF3 but not NF- $\kappa$ B activation in immune cells. *J. Immunol.* **191**, 6231–6240 (2013).
40. Kagan, J. C. et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon- $\beta$ . *Nat. Immunol.* **9**, 361–368 (2008).
41. Rehwinkel, J. & Gack, M. U. RIG-I-like receptors: their regulation and roles in RNA sensing. *Nat. Rev. Immunol.* **20**, 537–551 (2020).
42. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**, 101–105 (2006).
43. McCullough, J., Clague, M. J. & Urbe, S. AMSH is an endosome-associated ubiquitin isopeptidase. *J. Cell Biol.* **166**, 487–492 (2004).
44. Ritorto, M. S. et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. *Nat. Commun.* **5**, 4763 (2014).
45. Hatesuer, B. et al. Deletion of Irf3 and Irf7 genes in mice results in altered interferon pathway activation and granulocyte-dominated inflammatory responses to influenza A infection. *J. Innate Immun.* **9**, 145–161 (2017).
46. Channappanavar, R. et al. Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. *Cell Host Microbe* **19**, 181–193 (2016).
47. Crow, Y. J. & Stetson, D. B. The type I interferonopathies: 10 years on. *Nat. Rev. Immunol.* **22**, 471–483 (2022).
48. Rice, G. I. et al. Mutations in ADAR1 cause Aicardi–Goutieres syndrome associated with a Type I interferon signature. *Nat. Genet.* **44**, 1243–1248 (2012).
49. Stetson, D. B., Ko, J. S., Heidmann, T. & Medzhitov, R. Trex1 prevents cell-intrinsic initiation of autoimmunity. *Cell* **134**, 587–598 (2008).
50. Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. *N. Engl. J. Med.* **371**, 507–518 (2014).
51. Huang, Z. et al. Type I interferon signature and cycling lymphocytes in macrophage activation syndrome. *J. Clin. Invest.* **133**, e165616 (2023).
52. Ohyagi, H. et al. Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. *Immunity* **39**, 584–598 (2013).
53. Nguyen, T. T. T., Kim, Y. T., Jeong, G. & Jin, M. Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective. *Exp. Mol. Med.* **56**, 559–569 (2024).
54. Roger, T. et al. Protection from lethal Gram-negative bacterial sepsis by targeting Toll-like receptor 4. *Proc. Natl Acad. Sci. USA* **106**, 2348–2352 (2009).
55. Arimori, Y. et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. *Antivir. Res.* **99**, 230–237 (2013).
56. Loo, Y. M. et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. *J. Virol.* **82**, 335–345 (2008).
57. Murphy, A. A., Rosato, P. C., Parker, Z. M., Khalenkov, A. & Leib, D. A. Synergistic control of herpes simplex virus pathogenesis by IRF-3, and IRF-7 revealed through non-invasive bioluminescence imaging. *Virology* **444**, 71–79 (2013).
58. Rosato, P. C. & Leib, D. A. Neuronal interferon signaling is required for protection against herpes simplex virus replication and pathogenesis. *PLoS Pathog.* **11**, e1005028 (2015).
59. Reinert, L. S. et al. Sensing of HSV-1 by the cGAS–STING pathway in microglia orchestrates antiviral defence in the CNS. *Nat. Commun.* **7**, 13348 (2016).
60. Ames, J. et al. OPTN is a host intrinsic restriction factor against neuroinvasive HSV-1 infection. *Nat. Commun.* **12**, 5401 (2021).
61. Matsumoto, M. L. et al. K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. *Mol. Cell* **39**, 477–484 (2010).
62. French, M. E., Koehler, C. F. & Hunter, T. Emerging functions of branched ubiquitin chains. *Cell Discov.* **7**, 6 (2021).
63. Boname, J. M. et al. Efficient internalization of MHC I requires lysine-11 and lysine-63 mixed linkage polyubiquitin chains. *Traffic* **11**, 210–220 (2010).
64. Dynek, J. N. et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. *EMBO J.* **29**, 4198–4209 (2010).
65. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. *Nature* **424**, 743–748 (2003).
66. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* **301**, 640–643 (2003).

67. Zhao, B. et al. A conserved PLPLRT/SD motif of STING mediates the recruitment and activation of TBK1. *Nature* **569**, 718–722 (2019).
68. Tsuchida, T. et al. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. *Immunity* **33**, 765–776 (2010).
69. Zhang, J., Hu, M. M., Wang, Y. Y. & Shu, H. B. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. *J. Biol. Chem.* **287**, 28646–28655 (2012).
70. Wang, Q. et al. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. *Immunity* **41**, 919–933 (2014).
71. Prabakaran, T. et al. Attenuation of cGAS–STING signaling is mediated by a p62/SQSTM1-dependent autophagy pathway activated by TBK1. *EMBO J.* **37**, e97858 (2018).
72. Riley, B. E. et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. *Nat. Commun.* **4**, 1982 (2013).
73. Smit, J. J. et al. The E3 ligase HOIP specifies linear ubiquitin chain assembly through its RING-IBR-RING domain and the unique LDD extension. *EMBO J.* **31**, 3833–3844 (2012).
74. Liu, W. et al. E3 ubiquitin ligase ANKIB1 attenuates antiviral immune responses by promoting K48-linked polyubiquitination of MAVS. *Cell Rep.* **43**, 114687 (2024).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

<sup>1</sup>Cell Death, Inflammation and Immunity Laboratory, Institute of Biochemistry I, Faculty of Medicine, University of Cologne, Cologne, Germany.

<sup>2</sup>Cell Death, Inflammation and Immunity Laboratory, CECAD Cluster of Excellence, University of Cologne, Cologne, Germany. <sup>3</sup>Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, London, UK. <sup>4</sup>CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. <sup>5</sup>Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain. <sup>6</sup>Department of Microbiology, Paediatrics, Radiology and Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain. <sup>7</sup>Department of Pathology, University of Cambridge, Cambridge, UK. <sup>8</sup>Mildred Scheel School of Oncology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Translational Genomics, Cologne, Germany. <sup>9</sup>Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany. <sup>10</sup>Cologne Centre for Genomics, Medical Faculty, University of Cologne, Cologne, Germany. <sup>11</sup>Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain. <sup>12</sup>Institute of Biochemistry, Department of Chemistry, Faculty of Mathematics and Natural Sciences, University of Cologne, Cologne, Germany. <sup>13</sup>These authors contributed equally: Alexis Betrancourt, M. Talha Cinko.

<sup>14</sup>These authors jointly supervised this work: Eva Rieser, Henning Walczak. ✉ e-mail: [erieser@uni-koeln.de](mailto:erieser@uni-koeln.de); [h.walczak@uni-koeln.de](mailto:h.walczak@uni-koeln.de)

## Methods

All animal procedures were conducted in accordance with European, national and institutional guidelines and approved by local government authorities (LAVE NRW; permission Az. 81-02.04.2020.A022). Study protocols and animal experiments performed in Zaragoza were approved by the Animal Experimentation Ethics Committee of the University of Zaragoza (numbers PI18/2, PI18/23, PI62/22 and PI24/25) and in accordance with institutional, national and European ethical animal regulations (Protection of Animals Act).

### Generation of ANKIB1 expression constructs

The coding sequence of ANKIB1 was amplified using Phusion High-Fidelity PCR Master Mix (New England Biolabs) and cloned to the pBABE-Puro plasmid using XhoI and AgeI (New England Biolabs). Deletions and point mutations were introduced to into the plasmid using the primers presented in Supplementary Table 1 with the Q5 Site-Directed Mutagenesis kit (New England Biolabs) according to the manufacturer's instructions.

### Recombinant proteins, reagents and cell lines

E1, E2s, USP2 and ubiquitin were purchased from R&D systems. moTAP-TNF was produced and purified as described in ref. 75. Poly(I:C) HMW was purchased from Invivogen. LPS was purchased from Enzo Life Sciences. ADU-S100 was purchased from MedchemExpress and 2'3'cGAMP was purchased from Selleck Chemicals. All primers listed in Supplementary Table 1 were produced by Sigma-Aldrich.

WT HeLa (ATCC CCL-2), HT-29 (ATCC HTB-38) and A549 (ATCC CCL-185) cell lines used herein were purchased from the ATCC. ANKIB1 and TLR3 were depleted using the plasmid px458 with the respective gRNA sequences presented in Supplementary Table 1 and performing single-cell sorting upon transfection. TANK/NAP1/SINTBAD/OPTN were generated using the gRNA published in ref. 10. The generation of viral particles and reconstitution of cancer cell lines with different ANKIB1 mutants or TLR3-moTAP were performed as described previously<sup>10</sup>. Reconstituted cells were either selected via GFP-positive cell sorting by fluorescence-activated cell sorting (FACS) or via puromycin treatment.

### SDS-PAGE and western blotting

Proteins were separated using 4–15% Mini- or Midi-PROTEAN-TGXTM-gels (Bio-Rad) with Tris/glycine/SDS running buffer. Proteins were transferred on Mini- or Midi-0.2- $\mu$ m nitrocellulose membranes (Bio-Rad transfer packs) using the Trans-Blot Turbo Transfer System from Bio-Rad. Proteins were analysed by western blotting using the respective antibodies presented in Supplementary Table 2 and either LLC Western Lightning Plus ECL (Revvity Health Sciences) for chemiluminescent signal or a Li-Cor Odyssey CLx for fluorescent signal.

### Mice

C57BL/6N *Ankib1*<sup>-/-</sup> tm1a mice were developed by the European Conditional Mouse Mutagenesis Program using Knockout-First-Reporter Tagged Insertion allele technology. The mice used in this study were maintained and bred in the animal facility of the CECAD Research Centre, University of Cologne. Their microbiological status was examined as recommended by the Federation of European Laboratory Animal Science Associations and the mice were free of all listed pathogens.

### Isolation of BMDMs and splenocytes

Bone marrow isolation was performed as described previously<sup>10</sup>. Cells were plated in non-coated 10-cm dishes at a concentration of  $2 \times 10^6$  cells ml<sup>-1</sup> and treated with 20 ng ml<sup>-1</sup> M-CSF for 7 days. The cells were then detached with 10 mM EDTA for 10 min and plated in a 12-well plate for the experiments. Splenocytes were isolated from 8–12-week-old mice. Spleens were mashed on a 75- $\mu$ m filter and red blood cells were

removed as for BMDMs. Cells were counted and plated at  $2.5 \times 10^6$  cells ml<sup>-1</sup> in DMEM containing 1% L-glutamine and 1% penicillin/streptomycin with 10% decomplemented FBS.

### RNA isolation and RT-qPCR

Total RNAs from HeLa and HT-29 cells with or without the respective treatment were extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. From the cDNA generated by the Iscript Reverse Transcription Supermix (Bio-Rad), RT-qPCR was performed using Itaq Universal SYBR (Bio-Rad), with the primers listed in Supplementary Table 1 and the following conditions: initial polymerase activation step of 30 s at 95 °C, followed by 35 amplification cycles of 5 s at 95 °C and 30 s at 64 °C. Three technical replicates were generated for each sample and run on a Bio-Rad CFX Opus 96. GAPDH was used as reference gene and the relative expression of the gene transcripts was analysed using the 2<sup>- $\Delta$ Ct</sup> method.

For RT-qPCR after in vitro infection with either MVA or SeV, samples were collected with 250  $\mu$ l lysis buffer (4 M guanidine thiocyanate, 25 mM Tris-HCl pH 7 and 143 mM 2-mercaptoethanol) followed by the addition of 250  $\mu$ l 70% ethanol. Total RNA was extracted using a silica column (Epoch Life Science) and washed once with wash buffer 1 (1 M guanidine thiocyanate, 25 mM Tris-HCl pH 7 and 10% ethanol) and twice with wash buffer 2 (25 mM Tris-HCl pH 7 and 70% ethanol). Total RNA was eluted using nuclease-free water. Then 500 ng of RNA was used to produce cDNA using SuperScript III reverse transcriptase (Thermo Scientific) following the manufacturer's protocol. Samples were diluted and used as input in a 20  $\mu$ l reaction using the KAPA SYBR Fast System (Roche) following the manufacturer's protocol.

### RNA sequencing

Total RNA from HeLa cells treated with poly(I:C) were extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. RNA sequencing was performed by CeGaT GmbH. In brief, 10 ng RNA of each sample were used for library preparation with the SMART-Seq stranded total RNA kit (Takara). Libraries were sequenced on a NovaSeq 6000 machine (Illumina) with 2 $\times$ 100 bp. The sequencing reads were demultiplexed with Illumina bcl2fastq (2.20) and adaptors were trimmed with Skewer (version 0.2.2). Quality trimming of the reads was not performed. The raw counts derived from the mapping contain the number of reads that map to each gene ID. Based on these numbers, the normalized counts were calculated. Normalized counts were calculated with DESeq2 in R.

Total RNA from the spleen of poly(I:C)-injected mice were extracted using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. mRNA sequencing for mouse spleen samples was performed by Cologne Center for Genomics. Briefly, 3' mRNA libraries were generated from 200 ng (spleen samples) total RNA using the QuantSeq 3' mRNA-Seq FWD V2 Library Prep kit (Lexogen) according to the manufacturer's protocol and using 17 cycles for library amplification. After validation (using a TapeStation, Agilent Technologies) and quantification (Qubit, Thermo Fisher Scientific) individual libraries were pooled. The library pools were quantified using the Colibri Library Quantification kit (Thermo Fisher Scientific) and the QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific). The libraries were subsequently sequenced on an Illumina NovaSeq 6000 instrument using a 1 $\times$ 100 bp sequencing protocol and aiming for 10–12 million reads per sample.

### ELISA

Supernatants were collected upon respective treatment. Before freezing at -80 °C, samples were spun down for 10 min at 450g and the supernatants were transferred. The IFN $\beta$  ELISA was conducted following the manufacturer's protocol (R&D).

### Cell activation and immunoprecipitation

For cell activation followed by immunoprecipitation, cells were treated for the indicated times and then lysed in 1 ml lysis buffer (30 mM Tris-HCl pH 7.5, 120 mM NaCl, 1.7 mM DDM, 2 mM KCl, 2 mM EDTA, 10% glycerol, phosSTOP (Roche) and EDTA-free protease inhibitor cocktail (Roche)) at 4 °C for 20 min before centrifugation at 17,500g at 4 °C for 30 min. Subsequently, the cell lysates were incubated with M2 anti-Flag magnetic beads (Sigma-Aldrich) overnight at 4 °C. The following day, beads were washed five times with lysis buffer and proteins were eluted by boiling in reducing sample buffer. Samples were analysed by western blotting as previously described.

### Production of TUBE and deubiquitinases

The coding sequence of AMSH was cloned into the GEX6-P2 vector. pOPINK-Cezanne (OTU, aa 53–446) was a gift from David Komander (Addgene plasmid #61581; RRID: Addgene\_61581). The glutathione S-transferase (GST)-tagged TUBE (GST-TUBE) was previously described<sup>76</sup>. Expression vectors were transformed into BL21 (DE3) bacteria and the respective proteins were purified as described previously<sup>75</sup>. After purification, the GST tag was removed from AMSH and Cezanne using human rhinovirus 3C protease (Cytiva 27084301) according to the manufacturer's instructions. The protein concentration was measured with a Nanophotometer (Implen).

### In vitro ubiquitin assay

MoTAP tagged-ANKIB1 WT and ΔRING2 were purified by Flag-tag. The amount and quality of purification was assessed by Coomassie brilliant blue G-250. Different versions of ANKIB1 were incubated for 1 h at 37 °C in a 30 μl reaction mixture containing either 200 nM UBA1; 1 μM UBE2L3, 1 μM UBE2D3 or 1 μM UBE2L6; 100 μg ml<sup>-1</sup> ubiquitin (R&D systems); 2 mM DTT; 30 mM Tris-HCl, pH 7.5; 5 mM MgCl<sub>2</sub> and 1× Energy Regenerating Solution (Enzo Life Sciences). For negative controls, ubiquitin buffer was added instead of the E1 and E2. Afterward, the samples were analysed by western blot. For subsequent deubiquitinase assay, ANKIB1 was removed with M2-Flag beads and either USP2 or Cezanne were added at a concentration of 1 μM and 0.5 μM, respectively, and samples were incubated at 30 °C for 1 h. The reaction was terminated by adding and boiling in reducing sample buffer.

### K11-Ub antibody production

The amino acid sequence of the K11-Ub linkage-specific 2A3/2E6 antibody was as previously described<sup>60</sup>, and the coding sequence was synthesized by Thermo Scientific and cloned into the pVITRO plasmid using AgeI, BsrGI, BspEI and BamHI restriction enzymes (New England Biolabs). The antibody was transiently expressed in Expi293F cells (Gibco, A14527) and purified using a Protein G column (Sigma-Aldrich, GE17-0618-01).

### TUBE PD and in vitro deubiquitination assay

HeLa WT, ANKIB1-deficient and stably expressing RING1-mutant ANKIB1 cells were treated with either poly(I:C) or 2'3'cGAMP for the indicated times and then sonicated and lysed in denaturing TUBE PD lysis buffer (30 mM Tris-HCl pH 7.5, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 1 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 0.5% Triton-X 100 1% SDS, 10% glycerol, phosSTOP (Roche) and EDTA-free protease inhibitor cocktail (Roche)) and 45 μM PR619 DUB inhibitor (Selleckchem) at 4 °C for 30 min before centrifugation at 17,500g for 30 min. Samples were then diluted with SDS-free TUBE PD lysis buffer, thus decreasing the SDS concentration to 0.1%, and then incubated with glutathione sepharose beads (Cytiva) freshly pre-coupled with GST-TUBE (20 μg per sample) overnight at 4 °C. The following day, beads were washed with SDS-free TUBE PD lysis buffer and proteins were either eluted from beads by boiling with reducing sample buffer followed by immunoblotting or subjected to an 'in vitro deubiquitination assay' after washing beads twice with DUB reaction buffer (50 mM Tris-HCl pH 7.5 and 100 mM NaCl). In short,

the beads were incubated with 600 μg ml<sup>-1</sup> K48-tetraubiquitin chains (Adipogen) in DUB reaction buffer with 1 mM DTT at 37 °C for 30 min. Meanwhile, AMSH, Cezanne and USP2 (R&D Systems) were diluted to 2× the indicated concentrations in DUB dilution buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl and 1 mM DTT) and incubated at room temperature for 10 min. The respective DUBs were then mixed with the beads and incubated at 37 °C for 1 h. The reactions were terminated by boiling the samples in reducing sample buffer before analysis by immunoblotting.

### HSV-1 infection and disease monitoring

Age-matched (12–16-week-old) male WT littermate control ( $n = 8$ ) and *Ankib1*<sup>-/-</sup> ( $n = 5$ ) mice were anaesthetised in a mouse anaesthesia induction chamber with 2–3% isoflurane. Mice were infected intranasally with  $1 \times 10^6$  plaque-forming units (p.f.u.) of HSV-1 SC16 strain, using a total volume of 40 μl. Mice were weighed daily and a clinical score was applied when mice showed signs of disease. The clinical score evaluated mouse appearance, level of consciousness, activity, response to stimuli, eye appearance and frequency and quality of respiration, standardized to a five-point scale ranging from 0 to 4. The humanitarian end point was reached with a 25% weight loss, a score equal to or higher than 15 or if any respiratory characteristics increased by more than 3 (ref. 77). Mice were euthanized following human end point standards.

### Secondary HLH and *E. coli* sepsis model

The model of secondary HLH was performed using age-matched (8-week-old) female and male WT littermate control ( $n = 8$ ) and *Ankib1*<sup>-/-</sup> ( $n = 9$ ) mice as described previously<sup>78</sup>. For the sepsis model, a strain of *E. coli* isolated from the blood of a WT mouse with CLP-induced sepsis was used<sup>79</sup>. Sepsis was induced by inoculating  $2 \times 10^8$  colony-forming units in 200 μl of PBS to 8-week-old female and male WT littermate control ( $n = 9$ ) and *Ankib1*<sup>-/-</sup> ( $n = 8$ ) mice via intraperitoneal injection. The mice were weighed and observed daily, with sepsis scoring performed regularly, and survival monitored over 5 days. A humane end point was applied when the murine sepsis score exceeded 14 or when body weight loss was greater than 25%.

### IAV infection

Age-matched (12–16-week-old) WT littermate control ( $n = 7$ ) and *Ankib1*<sup>-/-</sup> ( $n = 7$ ) female and male mice were infected with a mouse-adapted pandemic influenza strain H1N1A/PR/8/3424 virus. The mice were anesthetized in a chamber with 2–3% isoflurane and intranasally infected with  $2 \times 10^3$  p.f.u. of IAV in 40 μl. The mice were weighed and observed daily, with sepsis scoring performed and survival monitored as described previously<sup>77</sup>.

### In vitro infection assays

Monolayers of HeLa or A549 cells in 6-well plates were washed once with PBS and infected with the indicated viruses at a multiplicity of infection of 5 (MVA, HSV-1 and IAV) or 1 (SeV) in diluted serum-free media for 2 h at 37 °C. Inoculum was then removed and replaced with complete DMEM. Cell lysates were collected on ice at the indicated time points with RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP40, 0.1% SDS and 0.5% Na Deoxycholate) supplemented with complete EDTA-free protease inhibitors and PhosSTOP phosphatase inhibitor cocktail for western blot analysis.

### nCounter RNA Analysis

At day 3 post-infection with HSV-1, brainstems of mice were isolated and subjected to RNA extraction using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. Total RNA was quantified using a spectrophotometer. For each reaction, 300 ng of purified total RNA was hybridized with nCounter Reporter and Capture probe sets (nCounter XT PGX MmV1 Cancer Immune) according to the manufacturer's protocol. Hybridization was performed in a total volume of 15 μl at 65 °C for 18 h. Following hybridization, samples were loaded on the

nCounter cartridge using the nCounter Prep Station and data were collected with the nCounter digital analyser. Raw counts were normalized using the housekeeping genes included in the nCounter XT Codeset and the nSolver software's Basic Analysis tool. Normalized counts were exported for downstream analysis. Heat maps were generated using the heatmap function from the heatmap R package (vR 4.5.1).

Pathway analysis was performed with an overrepresentation test (Fisher's exact test) using PANTHER v19.0 and the Gene Ontology (GO) database (<https://doi.org/10.5281/zenodo.15066566>, released on 16 March 2025). In brief, downregulated genes with a moderate to high effect ( $\log_2FC < -0.5$ ) were used as a gene list and the entire gene panel measured by the nCounter assay was used as the background. Gene symbols were used as identifiers.

### K11-Ub immunoprecipitation

HeLa WT and ANKIB1-deficient cells were treated with poly(I:C) for the indicated times and lysed in denaturing K11 immunoprecipitation-lysis buffer (30 mM Tris-HCl pH 7.5, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 1% Triton-X 100, 1% SDS, 10% glycerol, phosSTOP, EDTA-free protease inhibitor cocktail and 45  $\mu$ M PR619 DUB inhibitor) and processed as described in TUBE PD but then incubated with protein G-beads freshly pre-coupled with K11 antibody overnight at 4 °C. The following day, beads were washed with SDS-free K11 immunoprecipitation-lysis buffer and proteins were eluted by boiling them in reducing sample buffer. Samples were analysed by immunoblotting.

### Cytokine/chemokine quantification

Lung samples were obtained from a weighed portion of murine lung, homogenized in 500  $\mu$ l DMEM with a GentleMACS dissociator (Miltenyi) and centrifuged (900g for 5 min). The addition of 0.5% Triton-X 100 and protease inhibitor (Complete, Roche) to the homogenates inactivated the virus and prevented degradation.

The multiplex ELISA was performed via a custom Luminex Discovery assay (R&D Bio-Techne) according to the manufacturer's instructions. Samples were centrifuged at 10,000g for 5 min and diluted at a 1:2 ratio in Calibrator Diluent (R&D Bio-Techne) before analysis. Samples were measured with a Luminex 200 xMAP system (Luminex) and xPONENT software was used for data collection and analysis.

### Ubiquitin linkage type identification

For the in vitro ubiquitin assay, samples were prepared for mass spectrometry analysis after in-gel digestion overnight with trypsin. All samples were analysed by the CECAD Proteomics Facility on a Q Exactive Plus Orbitrap mass spectrometer coupled to an EASY nLC (both Thermo Scientific). Peptides were loaded with solvent A (0.1% formic acid in water) onto an in-house packed analytical column (50 cm, 75  $\mu$ m inner diameter, filled with 2.7  $\mu$ m Poroshell EC120 C18, Agilent). Peptides were chromatographically separated at a constant flow rate of 250 nl min<sup>-1</sup> using the following gradient: 3–5% solvent B (0.1% formic acid in 80% acetonitrile) within 1.0 min, 5–30% solvent B within 121.0 min, 30–40% solvent B within 19.0 min, 40–95% solvent B within 1.0 min, followed by washing and column equilibration. The mass spectrometer was operated in data-dependent acquisition mode. The MS1 survey scan was acquired from 300 to 1750 *m/z* at a resolution of 70,000. The top ten most abundant peptides were isolated within a 1.8-Th window and subjected to HCD fragmentation at a normalized collision energy of 27%. The AGC target was set to 5e5 charges, allowing a maximum injection time of 110 ms. Product ions were detected in the Orbitrap at a resolution of 35,000. Precursors were dynamically excluded for 10.0 s.

All mass spectrometric raw data were processed with Maxquant v2.0.3.0 (ref. 80) using default parameters against the Uniprot canonical Human database (UP5640, downloaded 26 August 2020) with the match-between-runs option enabled between replicates. Follow-up analysis was done in Perseus 1.6.15 (ref. 81). Protein groups were filtered

for potential contaminants and insecure identifications. The log<sub>2</sub> intensities values of the different linkage types found in the samples were used to identify their respective abundance.

### Statistics and reproducibility

All data collection and analysis for in vivo experiments were performed blindly by three researchers. GraphPad Prism V9.4 software (Graphpad) was used for statistical analyses. The normality of all data was confirmed using Anderson–Darling or Shapiro–Wilk tests. Error bars denote either s.e.m. or s.d. The statistical significance of data was assessed by either two-way analysis of variance (ANOVA), uncorrected Fisher's least significant difference (LSD) multiple-comparisons test, unpaired two-tailed Student's *t*-test or Kolmogorov–Smirnov or Fisher's exact test with 95% confidence intervals. Survival curves were compared using a log-rank Mantel–Cox test with 95% confidence intervals. No statistical methods were used to predetermine sample sizes for in vivo experiments but our sample sizes are similar to those reported in previous publications<sup>59,78,79</sup>. Mice of the indicated genotype were randomly assigned to groups. No data were excluded from any experimental group.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

The mass spectrometry proteomics data (Fig. 2e) have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier [PXD065049](https://doi.org/10.26434/chemrxiv-2025-pxd06). The RNA datasets generated and analysed during the current study are not publicly available owing to ongoing scientific research but are available from the corresponding authors upon reasonable request. No custom codes were developed in this study. Source data are provided with this paper.

### References

- Draber, P. et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. *Cell Rep.* **13**, 2258–2272 (2015).
- Hjerpe, R. et al. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. *EMBO Rep.* **10**, 1250–1258 (2009).
- Shrum, B. et al. A robust scoring system to evaluate sepsis severity in an animal model. *BMC Res. Notes* **7**, 233 (2014).
- Wang, A. et al. Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice. *Proc. Natl Acad. Sci. USA* **116**, 2200–2209 (2019).
- Uranga-Murillo, I. et al. Biological relevance of Granzymes A and K during *E. coli* sepsis. *Theranostics* **11**, 9873–9883 (2021).
- Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.* **11**, 2301–2319 (2016).
- Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **13**, 731–740 (2016).

### Acknowledgements

We thank all members of the Walczak group for useful technical advice and fruitful scientific discussions, particularly M. Wakid for her support in preparation of the final manuscript. We thank the CECAD animal facility for generating *Ankib1*<sup>-/-</sup>tm1a mice. We also thank the members of the CECAD proteomics facility for valuable support and advice and K. Hofmann for valuable input and advice regarding ubiquitin linkage characterization.

H.W. is funded by the Alexander von Humboldt Foundation, a Wellcome Trust Investigator Award (no. 214342/Z/18/Z), a Medical Research Council Grant (no. MR/S00811X/1), a Cancer Research UK Programme grant (no. A27323), three collaborative research centre grants (SFB1399, project C06, SFB1530-455784452, SFB1399-413326622, project A03 and SFB1403-414786233) funded by the Deutsche Forschungsgemeinschaft (DFG) and the NRW Network grant CANTAR funded from the programme 'Netzwerke 2021', an initiative of the Ministry of Culture and Science of the State of Northrhine Westphalia. J.P. is funded by PID2020-113963RBIOO, ASPANO, FARO, Carrera de la mujer de Monzón, CIBERINFEC/ISCIII (CB21/13/00087), CERTERA/ISCIII (CERT22/00004), FORTALECE/ISCIII (FORT23/00028/03) and Aragon Government (Group B29\_23R). M.A. is funded by a Postdoctoral Juan de la Cierva Contract and postdoctoral CIBER contract and I.U.-M. received a PhD grant from the Aragón Government (no. BOA-2018-06-15-027). J.B. received funding from a Mildred Scheel Nachwuchszentrum grant 70113307 by the German Cancer Aid (Deutsche Krebshilfe), a collaborative research centre grant (SFB1399, Project C07) and the NRW Network grant CANTAR. RNA sequencing was supported by the DFG Research Infrastructure West German Genome Center (project no. 407493903) as part of the Next Generation Sequencing Competence Network (project no. 423957469). Next-generation sequence analyses were carried out at the production site Cologne (Cologne Center for Genomics). A.A. is funded by the Spanish Ministry of Science and Innovation and the European Union (European Regional Development's Funds, FEDER) (grant PID2021-128580OB-I00). B.J.F. is funded by UKRI BBSRC, BB/Y007212/1, UKRI MRC and UKRI430 grants. RNA sequencing was supported by the DFG Research Infrastructure West German Genome Center (project no. 407493903) as part of the Next Generation Sequencing Competence Network (project no. 423957469). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

## Author contributions

H.W. and E.R. conceived the project. A.B., M.T.C., H.W. and E.R. designed the experiments and A.B., M.T.C. and E.R. performed the majority of the experiments, with J.P., I.U.M., M.A. and N.P. helping in designing and performing the in vivo experiments. R.M. and A.A. contributed to the in vivo experiments. A.B.V., L.M.K. and B.B. supported in vitro experiments. A.B.V. and L.M.K. performed RNA and cytokine analysis. J.B., K.B. and R.C. performed the bioinformatic analysis of the RNA sequencing. L.F.C. and B.J.F. designed and performed in vitro infection experiments. D.d.M. generated essential tools for the study. A.B., M.T.C., E.R. and H.W. wrote the manuscript.

## Funding

Open access funding provided by Universität zu Köln.

## Competing interests

The authors declare no competing interests.

## Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41556-026-01886-z>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41556-026-01886-z>.

**Correspondence and requests for materials** should be addressed to Eva Rieser or Henning Walczak.


**Peer review information** *Nature Cell Biology* thanks Xuetao Cao, Ivan Dikic and Nan Yan for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).




**Extended Data Fig. 1 | ANKIB1 knockdown disrupts TLR3-induced TBK1 activation.** **a–c** HeLa WT cells were transfected with either 20 nM non-targeting control siRNA (siCtrl) or 20 nM siRNA targeting the respective mRNAs of interest, individually for 48 hours or in **b**, 72 hours. Subsequently, they were stimulated with 10  $\mu$ g/mL poly(I:C) as displayed and the lysates were subjected to western

blot analysis. The knockdown efficiency of the targets was assessed by RT-qPCR in **a**, **b** or immunoblotting in **c**. For the panel of the western blots and RT-qPCR, one representative experiment was displayed of three independent replicates. Non-specific bands were marked with an asterisk.




**Extended Data Fig. 2 | ANKIB1 enables TBK1 activation in TLR3 pathway but does not act in TNF signalling.** **a**, HT-29 ANK<sup>-/-</sup> and WT cells were stimulated with 100 ng/mL TNF for the indicated times and subjected to western blot analysis. Non-specific bands were marked with an asterisk. **b**, HT-29 ANK<sup>-/-</sup> and WT or in **c**, HeLa WT and ANK<sup>-/-</sup> cells were treated with 10 µg/mL poly(I:C) for the indicated time points. **d**, ANKIB1 expression between HeLa WT, ANK<sup>-/-</sup> cells, and HeLa

stably expressing moTAP-ANKIB1 WT cells. **e**, HeLa WT cells were stimulated with 1 µg/mL moTAP-TNF and subjected to the pulldown via its Flag-tag. The purified TNFR1 and co-immunoprecipitated proteins were analysed by immunoblotting. One representative experiment of four independent replicates was shown for each western blot panel.




**Extended Data Fig. 3 | Characterisation of ANKIB1's catalytic domain and its requirement for TLR3-induced TBK1 activation.** **a**, Purified moTAP-ANKIB1 WT was incubated with ubiquitin, E1, and different combinations of E2 enzymes in ATP regeneration solution for 1 h at 37 °C. All samples were resolved by SDS-PAGE and subjected to anti-ubiquitin immunoblotting. **b**, moTAP-ANKIB1 WT purified from HeLa cells was subjected to in vitro ubiquitination assay with UBE2D3 for 1 h at 37 °C. Then, the reactants were incubated with or without general deubiquitinase USP2 for 1 h at 30 °C. The samples were resolved by SDS-PAGE and subjected to anti-ubiquitin immunoblotting. **c**, A schematic illustration of putative domains of ANKIB1 and its different mutant versions were created in BioRender. *Cinko, M. T. (2025) <https://biorender.com/dm2lne6>*. Ankyrin1/2 domains, catalytic RBR domain, Ariadne domain, ubiquitin interactive

motif (UIM), flexible linker, moTAP tag (2xStrep and 1x Flag). **d**, HeLa ANK<sup>-/-</sup> reconstituted with either moTAP-ANKIB1 WT or RING2 mutant (C519S/ C522S/ C532S/ C537S/ C540S/ C545S/ C548S) (ANK RING2<sup>mut</sup>) were stimulated with 10 μg/mL poly(I:C) for the indicated time points. The lysates were analyzed by immunoblotting. **e**, HeLa ANK<sup>-/-</sup> reconstituted with either moTAP-ANKIB1 WT or ΔRING2 (ANK ΔRING2) were stimulated with 10 μg/mL poly(I:C) for the indicated time points. The lysates were analyzed by immunoblotting. **f**, Purified moTAP-ANKIB1 WT and ΔRING2 were subjected to in vitro ubiquitination assay with UBE2D3 and UBE2L3 for 1 h at 37 °C. All samples were resolved by SDS-PAGE and subjected to anti-ubiquitin and ANKIB1 immunoblotting. For western blot, one representative experiment was displayed of three independent experiments.



**Extended Data Fig. 4 | Contribution of ANKIB1 and the adaptor proteins in STING and RIG-I signalling.** **a**, A549 WT and ANK<sup>-/-</sup> or in **b**, HT-29 WT and ANK<sup>-/-</sup> cells were treated with 10 μg/mL ADU-S100. The lysates were analysed by western blot. **c**, HeLa cells stably expressing moTAP ANK WT cells were treated with 10 μg/mL ADU S-100. moTAP-ANKIB1 was pulled-down via its Flag-tag. Immunoprecipitated proteins were analysed by immunoblotting. **d**, HeLa cells stably expressing either moTAP ANK WT or ANK ΔUIM cells were treated with 10 μg/mL 2'3' cGAMP. The lysates were analysed by western blot. **e**, A549 WT and ANK<sup>-/-</sup> were treated with either 50 ng/mL, 100 ng/mL or 200 ng/mL of 3p-hpRNA. The lysates were analysed by western blot. **f**, IFNβ mRNA was measured by RT-qPCR 6 h after stimulation of HeLa WT and ANK<sup>-/-</sup> cells with


200 ng/mL 3p-hpRNA.  $P = 0.0818$ . **g**, A549 WT and ANK<sup>-/-</sup> cells were either treated with 200 ng/mL 3p-hpRNA or infected with SeV/IAV for the indicated times and subjected to western blot analysis. **h**, HeLa WT and OPTN<sup>-/-</sup> cells were treated with 200 ng/mL of 3p-hpRNA. The lysates were analysed by western blot. **i**, HeLa WT and TKO cells were treated with 10 μg/mL ADU S-100. The lysates were analysed by western blot. The graphs represent mean ± SEM of six independent experiments.  $P$  values were determined by two-way ANOVA with uncorrected Fisher's LSD test in 95% confidence interval. \* $P \leq 0.05$ ; \*\* $P \leq 0.01$ ; \*\*\* $P \leq 0.001$ ; \*\*\*\* $P \leq 0.0001$ . For western blot, one representative experiment of three independent replicates was displayed. Non-specific bands were marked with an asterisk.



Extended Data Fig. 5 | See next page for caption.

**Extended Data Fig. 5 | Role of ANKIB1 *ex vivo* and characterisation of *Ankib1*<sup>-/-</sup> mice.** **a**, Mendelian frequencies obtained from inter-crossing *Ankib1*<sup>-/-</sup> mice. **b**, ANKIB1 expression was evaluated in various mouse tissues by western blotting. One representative experiment of three independent biological replicates was shown. **c**, Graph represents the ratio in percent of spleen weight (g) to body weight (g) in littermate control (n = 11) and *Ankib1*<sup>-/-</sup> (n = 12) mice. *P* = 0.5639. **d**, Number of immune cells isolated from spleen digestion in littermate control (n = 4) and *Ankib1*<sup>-/-</sup> (n = 4) mice were measured by flow cytometry, using anti-CD45 staining. *P* = 0.5942. **e**, Representative images from various organs of 10-month-old littermate control and *Ankib1*<sup>-/-</sup> mice stained with H&E. One representative image of three independent biological replicates per genotype was shown. **f**, *Ankib1*<sup>+/-</sup> and *Ankib1*<sup>-/-</sup> BMDMs were stimulated with 5 µg/mL poly(I:C) for the indicated times, and the lysates were assessed by western blotting. **g, h**, *Ankib1*<sup>+/-</sup> and *Ankib1*<sup>-/-</sup> splenocytes were treated with either 200 ng/mL LPS or 5 µg/mL ADU S-100 for the indicated times, and the lysates were analysed by western blotting. **i**, *Ankib1*<sup>+/-</sup> and *Ankib1*<sup>-/-</sup> BMDMs were stimulated with 200 ng/mL 3p-hpRNA for the indicated times, and the lysates were assessed

by western blotting. In all western blot panels, one representative experiment of four independent biological replicates was shown. Graphical data shows mean ± SD of independent biological replicates per genotype. Statistical analysis was performed by unpaired two tailed Student's t-test in 95% confidence interval. **j**, Representative scheme of the "Unrecognized signalling axis ANKIB1-K11-Ub-OPTN in the downstream of different PRRs" was created in BioRender. *Cinko, M. T. (2025) <https://biorender.com/munm5yp>*. ANKIB1 is a crucial module of TLR3, TLR4-TRIF and STING-SCs and once recruited, it generates K-11 Ub chains on various signalling proteins, facilitating OPTN-TBK1 recruitment, thereby activation of TBK1. Other types of ubiquitin linkages are present, such as K-63, as well as mixed ubiquitin chains. TBK1 phosphorylates the IRF3-binding motif of TRIF and STING, initially enabling the recruitment of IRF3 and later its phosphorylation by TBK1, which induces interferon production consequently (left panel). However, TLR4-MyD88 signalling arm and another IFN-inducing SC, MAVS-SC does not require ANKIB1-K11 Ub-OPTN signalling axis for TBK1 activation (right panel).



**Extended Data Fig. 6 | Inflammatory response characterisation of *Ankib1*<sup>-/-</sup> mice in sHLH and HSV-1 infection model.** **a**, 5 mg/kg LPS were intraperitoneally administered to WT littermate control and *Ankib1*<sup>-/-</sup> mice and the survival rate was monitored over days. *P* values were determined using log-rank Mantel-Cox test in 95% confidence interval. *P* > 0.9999. **b**, **c**, **d**, **e** Different gene enrichment set analysis were performed using RNA samples from the spleen of WT littermate control and *Ankib1*<sup>-/-</sup> mice 3 and 6 hours after poly(I:C) injection. Statistical

significance of the data was determined using Kolmogorov-Smirnov test. **f**, The concentration of IL-6 in lung homogenates of WT littermate control (*n* = 4) and *Ankib1*<sup>-/-</sup> (*n* = 5) mice was measured by ELISA at 5 days post infection with HSV-1. *P* = 0.8060. Data shows independent biological replicates per genotype. Statistical analysis was performed by unpaired two tailed Student's *t*-test in 95% confidence interval.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- | n/a                                 | Confirmed  |
|-------------------------------------|--|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> A description of all covariates tested  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted<br><i>Give <math>P</math> values as exact values whenever suitable.</i>                            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes  |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated  |

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection	QPCR data were obtained from Bio-Rad CFX Opus 96. Imaging data was collected by using S360, Hamamatsu Slidescanner with Autoloader, 40X objective. LC MS/MS was obtained from was performed on an Orbitrap Exploris 480 mass spectrometer. ELISA was quantified by using tecan infinite m200 pro.
Data analysis	Quantifications were performed with Microsoft Excel Itsc professional plus 2024, and statistical analysis was performed with GraphPad Prism V9.4. Images and figures were processed with Affinity Publisher 2. LC MS/MS data were analysed with Perseus and MaxQuant. RNA sequencing was analysed using R version 4.5.1 and pheatmap R package. Pathway analysis was performed using either Broad GSEA tool in preranked mode or PANTHER v19.0 and the GO Ontology database.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The mass spectrometry proteomics data (Fig. 2e) have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD065049. Source data are provided with this paper. The RNA datasets generated and analyzed during the current study are not publicly available due to ongoing scientific researches but are available from the corresponding author upon reasonable request. No custom codes were developed in this study. Source data are provided with this paper.

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

### Reporting on sex and gender

*Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design; whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data, where this information has been collected, and if consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.*

### Reporting on race, ethnicity, or other socially relevant groupings

*Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status). Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data, social media data, etc.) Please provide details about how you controlled for confounding variables in your analyses.*

### Population characteristics

*Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."*

### Recruitment

*Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.*

### Ethics oversight

*Identify the organization(s) that approved the study protocol.*

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

### Sample size

No statistical power calculation was performed prior to the in vivo infection experiments. Sample sizes were based on commonly used group sizes in comparable studies and were deemed sufficient to detect biologically meaningful differences between genotypes. The observed difference in survival between wild-type and knockout mice was large and unambiguous, hence statistical power was not a limiting factor for interpretation.

### Data exclusions

No data was excluded from any experimental group.

### Replication

All biological experiments were carried out under clearly defined and standard conditions and were repeated at least twice whenever possible. All replication attempts were successful.

### Randomization

Mice were randomly allocated to experimental groups.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern
<input checked="" type="checkbox"/>	<input type="checkbox"/> Plants

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

anti-ARIH1 (Novus Biology, NBP1-55039, Rabbit, 1/1000) anti-ARIH2, monoclonal (EPR7670) (Abcam, ab133744, Rabbit, 1/1000) anti- $\beta$ -Actin (ACTB), monoclonal (AC-15) (Sigma, A5441, Mouse, 1/10000) anti-ANKIB1 (Atlas Antibody, HPA021780, Rabbit, 1/750) anti-cullin 9 (ThermoFisher, A300-098A-T, Rabbit, 1/1000) anti-GAPDH (Sigma, G9545, Rabbit, 1/10000) anti-IRF3, monoclonal (D83B9) (Cell Signalling, 4302, Rabbit, 1/1000) anti-IkBa (Cell Signalling, 9242, Rabbit, 1/1000) anti-HOIP (Ubiquigent, 68-0013-100, Sheep, 1/500) anti-NEMO (IKK $\gamma$ ) (Atlas Antibodies, HPA000426, Rabbit, 1/1000) anti-RIPK1, monoclonal (D94C12 XP<sup>®</sup>) (Cell Signalling, 3493, Rabbit, 1/1000) anti-OPTN (Proteintech, 10837-1-AP, Rabbit, 1/5000) anti-Phospho-IkBa (Ser32/36), monoclonal (5A5) (Cell Signalling, 9246, Mouse IgG1, 1/750) anti-IRF3 (phospho S386), monoclonal (EPR2346) (Abcam, ab76493, Rabbit, 1/1000) mouse anti-phospho-IRF3 (396), monoclonal (E.875.8) (Thermo Scientific, MA5-14947, Rabbit, 1/500) anti-phospho-SAPK/JNK (Thr183/Tyr185), monoclonal (G9) (Cell Signalling, 9255, Mouse IgG1, 1/1000) anti-phospho-p38 MAPK (Thr180/Tyr182), monoclonal (3D7) (Cell Signalling, 9215, Rabbit, 1/1000) anti-phospho-NF- $\kappa$ B p65 (Ser536), monoclonal (93H1) (Cell Signalling, 3033, Rabbit, 1/1000) anti-phospho-TBK1/NAK (Ser172), monoclonal (D52C2 XP<sup>®</sup>) (Cell Signalling, 5483, Rabbit, 1/1000) anti-RNF14, monoclonal (EPR9041) (Abcam, ab134927, Rabbit, 1/1000) anti-RNF216 (Abcam, ab226215, Mouse IgG1, 1/1000) anti-TBK1 (Cell Signalling, 3013, Rabbit, 1/1000) anti-TLR3, monoclonal (D10F10) (Cell Signalling, 6961, Rabbit, 1/1000) anti-TNFR1, monoclonal (H-5) (Santa Cruz, 8436, Mouse IgG2b, 1/1000) anti-TRIF (Cell Signalling, 4596, Rabbit, 1/200) mouse anti-phospho-STING (Ser365), monoclonal (D8F4W) (Cell Signalling, 72971, Rabbit, 1/500) human anti-phospho-STING (S366), monoclonal (D7C3S) (Cell Signalling, 19781, Rabbit, 1/500) anti-STING, monoclonal (D2P2F) (Cell Signalling, 13647, Rabbit, 1/500) anti-TRAF3, monoclonal (D1N5B) (Cell Signalling, 61095, Rabbit, 1/500) anti-phospho-STAT1 (Y701), monoclonal (58D6) (Cell Signalling, 9167, Rabbit, 1/1000) anti-ubiquitin (Sigma-Aldrich, U5379, Rabbit, 1/1000) anti-Actin, monoclonal (mAbcam 8226) (Abcam, ab8226, Mouse IgG1, 1/10000) anti-VACV antibody (Abcam, ab19970, Rabbit, 1/1000), anti-Mouse IgG1-HRP (Southern Biotech, 1070-05, Goat, 1:10000) anti-Mouse IgG2b-HRP (Southern Biotech, 1091-05, Goat, 1:10000) anti-Rabbit IgG-HRP (Southern Biotech, 4050-05, Goat, 1:10000) anti-Sheep IgG-HRP (Southern Biotech, 6150-05, Rabbit, 1:10000) anti-Human IgG-HRP (Thermo Scientific, 31482, Goat, 1:10000) anti-Rabbit IgG 680 nm (Licor, 926-68071, Goat, 1:10000) anti-Mouse IgG 800 nm (Licor, 926-32210, Goat, 1:10000)

### Validation

Most of the listed antibodies have been used in our laboratory for many years and have been carefully validated using knockout MEFs (Lafont et al., 2018) or more recently via different techniques including siRNA kd, CrispR (Chen et al., 2024 and present study). Many antibodies were also validated by the provider as stated on their website.

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)	WT HeLa (ATCC CCL-2), HT-29 (ATCC HTB-38), and A549 (ATCC CCL-185) cell lines were purchased from ATCC.
Authentication	Authentication was not performed as none of the cells used have been listed in the commonly misidentified lines.
Mycoplasma contamination	All cell lines were negatively tested for mycoplasma using the MycoAlert™ Mycoplasma Detection Kit (LONZA)
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No misidentified lines were used in this study

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals	C57BL/6N Ankib1 <sup>-/-</sup> tm1a mice have been developed by EUCOMM (European Conditional Mouse Mutagenesis Program) using the Knockout-First-Reporter Tagged Insertion allele technology. Eight to twelve-week old C57BL/6N Ankib1 <sup>-/-</sup> and Ankib1 <sup>+/-</sup> mice were used for ex vivo experiment. Age matched (12-16 weeks old) Ankib1 <sup>-/-</sup> and wt littermate mice were used for IAV infection. 8 weeks old Ankib1 <sup>-/-</sup> and wt littermate mice were used for secondary HLH and E. coli sepsis model. Age-matched (12-16 weeks old) Ankib1 <sup>-/-</sup> and wt littermate control mice were used for HSV-1 infection. Ten-month-old Ankib1 <sup>-/-</sup> and wt littermate control mice were used for the phenotypic characterisation.
Wild animals	No wild animals were used
Reporting on sex	Findings do not apply to only one sex. In vivo and ex vivo results were obtained in males and females without distinction. Male only were used during HSV-1 infection experiment for availability reason
Field-collected samples	<i>For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.</i>
Ethics oversight	Mice were maintained in the animal facility of the CECAD Research Center, University of Cologne, in individually ventilated cages under a 12-h light/12-h dark cycle on sterilized bedding with access to a sterilized commercial pelleted diet and acidified water ad libitum as stated in FELASA. All animal procedures were conducted in accordance with European, national and institutional guidelines and approved by local government authorities (LAVE NRW; permission Az. 81-02.04.2020.A022). Study protocols and animal experiments performed in Zaragoza were approved by the Animal Experimentation Ethics Committee of the University of Zaragoza (numbers: PI 18/2, PI 18/23, PI 62/22, PI 24/25) and in accordance with institutional, national and European ethical animal regulations (Protection of Animals Act).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Plants

Seed stocks	<i>Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.</i>
Novel plant genotypes	<i>Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.</i>
Authentication	<i>Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.</i>